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ABSTRACT 
Identifying mechanisms underlying the synergistic pathological interaction between 
stroke and Alzheimer’s disease (AD) can effectively guide future therapeutic strategies 
for these highly co-morbid conditions. Aberrant ganglioside expression marked by the 
pathological accumulation of ganglioside GM3 is common to stroke and AD, yet it is 
unclear whether GM3 is synergistically enhanced in a comorbid model, or if GM3 is a 
viable therapeutic target. Adult male Wistar rats received a unilateral ischemic striatal 
infarct via endothelin-1 (ET-1) injection alone or in combination with bilateral 
intracerebroventricular injection of the β-Amyloid 25-35 peptide (Aβ) to induce 
generalized Aβ toxicity (Aβ/ET-1). Animals were sacrificed after 3 or 21 days and 
assessed via immunohistochemistry for neuroinflammation, neurodegeneration, and 
ganglioside expression. Other animals were also treated with chloroquine (CQ) 
systemically for seven days beginning 3 days before surgery as a novel therapeutic 
approach to prevent the accumulation of GM3 by inhibiting degradation of complex 
gangliosides. Our results showed that Aβ/ET-1 synergistically enhanced GM3 
accumulation with concomitant reductions in complex gangliosides and neuronal survival 
at 21 days. CQ reduced inflammation and GM3 accumulation at 21 days, and improved 
neuronal survival. These findings suggest GM3 accumulation is a point of synergism 
between stroke and Aβ toxicity, and CQ may be a viable therapeutic approach for stroke.  
Key Words: Alzheimer’s Disease, Aβ, Stroke, Neuroinflammation, Gangliosides, GM3, 
Chloroquine 
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1.1 Alzheimer’s Disease 
Alzheimer’s disease (AD) is synonymous with the elderly, yet in the context of the 
human species it is a relatively young disease. First characterized just over a century ago, 
AD is a devastating disease whose primary risk factor is age (Hardy and Allsop, 1991), 
and thus represents a significant impending burden upon the industrialized nations of the 
world with aging populations. AD is the most common (Querfurtth and LaFerla, 2010) 
and most aggressive (Humpel, 2011) form of dementia, as well as one of the most 
complex diseases of the central nervous system (CNS) as its pathogenesis is distinct from 
the normal aging process, yet inextricably linked to it (Hardy and Allsop, 1991).  
AD is a progressive disease resulting in severe synaptic loss, generalized cortical 
atrophy and dementia (Katsman and Saitoh, 1991). There are some autosomal dominant 
genetic mutations that are known to cause early-onset AD, or familial AD (FAD) (van 
Duijn et al., 1991), however estimates are that these only represent 1-10% of patients, and 
the vast majority of patients are classified as sporadic AD (Zlokovic, 2008; Yu et al., 
2010) because the cause is not known. In sporadic AD, the disease rarely manifests 
clinically before the age of 65, and is generally believed to be the result of the 
accumulation and deposition of β-amyloid (Aβ) over many decades which triggers a 
pathological cascade marked by the accumulation of hyperphosphorylated tau, synapse 
loss, neuronal death, and ultimately dementia (Hardy and Allsop, 1991; Hardy and 
Higgins, 1992; Hardy and Selkoe, 2002).  
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1.2 Aβ – The Hallmark of AD 
AD is characterized by various neuropathological markers, including synaptic and 
neuronal loss, intraneuronal neurofibrillary tangles and the distinctive presence of 
amyloid plaques (Hardy and Higgins, 1991, 1992; Katsman and Saitoh, 1991; Nelson et 
al., 2009). Diagnosis of AD is dependent on the presence of amyloid plaques (Herrup, 
2010), which are comprised mainly of insoluble fibrils of Aβ peptides (Glenner and 
Wong, 1984). Aβ is formed from amyloid precursor protein (APP) (Kang et al., 1987), a 
transmembrane protein whose physiological function is poorly understood (Tsuruma et 
al, 2010). Aβ is a 39-42 amino acid peptide (Lee et al., 1991) generated via the sequential 
cleavage of APP by β- and γ-secretase (Haass et al., 1992; Steiner and Haass, 2000). C-
terminal fragments of APP resulting from β-secretase cleavage can be cleaved at a variety 
of sites within the transmembrane domain by γ-secretase, releasing a variety of Aβ 
peptides that can spontaneously oligomerize into soluble aggregates, and eventually form 
the insoluble fibrils found in amyloid plaques (Crowther, 1991; Hardy and Higgins, 
1992). Amyloid plaques are resistant to proteolysis and are characteristically surrounded 
by dystrophic neurites as well as reactive microglia and astrocytes (Hardy and Allsop, 
1991).  
The physiological function of APP is far from clear, as although it is associated 
with the cytotoxic effects of Aβ (Kowall et al., 1991; Hardy and Higgins, 1992), APP 
knock-out (KO) mice display metabolic abnormalities and behavioural deficits (Hiltunen 
et al., 2009), specifically learning impairments and underlying synaptic defects (Ring et 
al., 2007; Dawson et al., 1999). APP can undergo alternative non-amyloidogenic 
processing by α- and γ-secretase, which precludes the formation of Aβ peptides (Tamboli 
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et al., 2005): α-secretase cleaves APP within the Aβ domain (Tamboli et al., 2005) 
producing p3 and soluble APPα (sAPPα), which is associated with neuroprotection 
(Fahrenholz, 2007; Tsuruma et al., 2010).  
A variety of factors can influence the expression of Aβ, such as intracellular 
cholesterol levels which is believed to affect Aβ production indirectly via the 
redistribution of APP and α/β secretases between distinct membrane microdomains 
(Reviewed by Tamboli et al., 2005). The most significant genetic risk factor for 
developing sporadic AD is the apo-lipoprotein E4 (ApoE4) allele, which is also 
associated with susceptibility to hypercholesterolemia (Prasher et al., 2008). Lowering 
cholesterol levels with statin therapy was shown to reduce the risk of developing AD in 
observational studies, however there was conflicting data from subsequent clinical trials 
(Jones et al., 2008; Sparks et al, 2005). Neuronal stressors (Abe et al., 1991), cytokines 
(Goldgaber et al., 1989; Ge and Lahiri, 2002) and even Aβ can increase expression of 
APP (Davis-Salinas et al. 1995; Schmitt et al. 1997), while Aβ deposition occurs 
following acute neuronal injury in both humans and animals (Kawarabayashi et al., 
1991). 
1.3 The Amyloid Cascade Hypothesis 
The amyloid cascade hypothesis posits that the accumulation of Aβ is the primary 
event that triggers the pathological cascade in all cases of AD, both sporadic and genetic 
(Hardy and Allsop, 1991; Hardy and Higgins, 1992). Neuropathological events such as 
synapse loss, neuroinflammation, formation of neurofibrillary tangles, altered neuronal 
ionic homeostasis, oxidative stress and neuronal loss were originally believed to be a 
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consequence of amyloid plaque concentrations reaching a certain threshold in the brain 
(Hardy and Higgins, 1992; Iwata et al., 2005; Selkoe, 2001; Hardy & Selkoe, 2002; 
Forman et al., 2004), however small soluble oligomers of amyloid are now thought to be 
the initiating factor for AD (Tam and Pasternak, 2012; Benilova et al., 2012).  
The strongest evidence that Aβ plays a causal role in AD is from the rare genetic 
forms of FAD; mutations in APP or Presenilin (PSEN) – the catalytic subunit of the γ-
secretase complex responsible for liberating Aβ from APP – genes can result in the 
accelerated accumulation of Aβ or the relative amount of Aβ42 to Aβ40, respectively, 
and are sufficient to cause early-onset AD (Hardy and Allsop, 1991; Benilova et al., 
2012; Yu et al., 2010; Zlokovic, 2008). Since the APP gene is located on chromosome 
21, individuals with Down’s syndrome harbor an extra copy of the APP gene and 
invariably develop pathological signs indistinguishable from early-onset AD via gene 
duplication (Hardy and Allsop, 1991). The sequential pathology in individuals with 
Down’s syndrome further supports the causative role of Aβ in AD, as the accumulation 
of Aβ is the first detectable pathological change (Rumble et al., 1989), followed much 
later by neurofibrillary tangles and loss of neurons (Mann, Royston and Ravindra, 1990).  
In sporadic cases of AD, Aβ accumulation is not a result of overproduction, but 
due to age-related failures in Aβ clearance mechanisms (Reviewed by Zlokovic, 2008). 
The amyloid cascade hypothesis is well established, if not accepted as fact, for genetic 
cases of AD (Hardy and Selkoe, 2002). AD pathogenesis is not as well understood for 
sporadic cases of AD, however it is believed that once the concentration of Aβ has 
reached a certain threshold, the amyloid cascade is initiated and the disease follows the 
same pathway to dementia as the genetic forms of AD (Hardy and Higgins, 1992; Herrup, 
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2010) and is the rationale behind a non-transgenic animal model of AD established by 
our lab (Whitehead et al., 2005a, b, 2007).  
1.4 Autophagy in AD 
One clearance mechanism that shows an age-related decline is autophagy, a 
lysosomal-mediated pathway that serves to provide cells with metabolic substrates to 
meet energy demands during nutrient deprivation or other stressful conditions, and a 
primary defense mechanism for selectively clearing old and damaged organelles or large 
intracellular protein aggregates, such as Aβ, from a cell (Seglen et al., 1996; Mortimore 
and Schworer, 1977; Yu et al., 2005; Rami, 2009). Autophagy is especially important for 
cells such as neurons and myocytes that do not divide after differentiating, as it represents 
a cellular adaptation to stress (Rami, 2009). Over-activation of autophagy can lead to cell 
death due to cellular atrophy (Nixon, 2007), while impaired autophagic function increases 
neuronal vulnerability in AD (Cataldo et al., 1996; Herrup, 2010).  
There is an age-associated decline in proteolytic activity causing a disruption in 
lysosomal, and therefore autophagic, function (Yu et al., 2005). This leads to the 
accumulation and enlargement of autophagic vacuoles (AVs) whose contents cannot be 
degraded, and is identifiable early in sporadic AD and Down’s syndrome and precedes 
extra-neuronal Aβ deposition and plaque formation (Cataldo et al., 2000; Molander-
Melin et al., 2005). The acidification of lysosomes (pH 4.5) is required for efficient 
autophagy, and is facilitated in part by by the presenilins (Lee et al., 2010). PSEN1 
mutations not only promote the generation of toxic Aβ42 species, but have also been 
shown to prevent lysosomal acidification (Lee et al., 2010), effectively impairing 
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autophagy and the cell’s ability to clear Aβ aggregates and hyperphosphorylated tau, 
resembling an adult-onset lysosomal storage disease (Tam & Pasternak, 2012). 
1.5 From Aβ to AD 
Despite the central role ascribed to Aβ in the pathogenesis of AD, the 
accumulation of Aβ does not always precipitate the disease, as the presence of amyloid 
plaques does not predict disease severity (Benilova et al., 2012). The abnormal 
accumulation and deposition of Aβ occurs many years prior to the onset of cognitive 
impairment (Benilova et al., 2012) and while the presence of Aβ is necessary for the 
diagnosis of AD, approximately 40% of non-demented individuals met diagnostic criteria 
for AD based strictly on Aβ plaque levels in the brain (Bennett et al., 2006, Price et al., 
2009). Transgenic mouse models of APP-overexpression show no neurodegeneration 
despite Aβ plaque formation and neuroinflammation (Benilova et al., 2012; Abramowski 
et al., 2012), and this discrepancy between neuronal loss and Aβ deposition in animal 
models and the human disease is highly controversial. 
In vitro studies found that among naturally occurring Aβ peptides, Aβ1-42 - which 
is less prevalent in vivo than Aβ1-40 - demonstrated the greatest tendency to aggregate, as 
well as the greatest toxicity towards cultured hippocampal neurons (Yankner et al., 1990; 
Selkoe, 1998; Iwata et al., 2005; Querfurth and LaFerla, 2010). Amino acid substitutions 
in the Aβ peptide sequence that enhanced aggregation of the peptide also enhanced the 
neurotoxicity of the peptide in vitro (Pike et al., 1995). While the fibrillization of Aβ is 
considered by some to be a key pathogenic process in AD (Yanagisawa et al., 2011), 
soluble aggregates of Aβ are now the focus of the amyloid hypothesis of AD as they have 
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shown greater neurotoxicity than the insoluble fibrils found in plaques (Kayed et al., 
2003; Glabe, 2008), and neuronal and synaptic loss has been shown to correlate with 
levels of soluble Aβ in AD brains (Lue et al., 1999; Naslund et al., 2000). It is 
intrinsically difficult to identify or accurately define which soluble species are 
pathogenic, as Aβ peptides are a heterogeneous mixture of peptides of differing solubility 
and stability (Benilova et al., 2012) that can aggregate into a variety of structures from 
soluble dimers, trimers and oligomers, to the insoluble fibrils found in plaques (Selkoe, 
2002; Walsh and Selkoe, 2007; Lacor et al., 2007; Lesne et al., 2006), all with different 
biological and toxic properties. The synthetic Aβ25-35 fragment - termed the ‘active’ 
fragment (Yankner et al., 1990) - is a convenient tool to study Aβ toxicity as it can induce 
similar toxicity mechanisms in vitro and in vivo as the full-length Aβ peptides (Yankner 
et al., 1990; Pike et al., 1995; Tsuruma et al., 2010; El Khoury et al., 1996; Frozza et al., 
2009), is able to aggregate into soluble oligomers (Kowall et al., 1992), and has been 
isolated from AD patients’ brains (Kubo et al., 2002). 
1.6 Cerebral Amyloid Angiopathy  
Aβ accumulation is not only damaging to the neuronal architecture of the brain, 
but the cerebrovasculature as well (Grammas et al., 2002). Aβ can deposit into the walls 
of the microvessels of the brain, leading to a condition known as cerebral amyloid 
angiopathy (CAA) which is present in 70-90% of AD cases (Greenberg et al., 2004; 
Smith and Greenberg, 2009). CAA typically affects small arteries, such as pial and 
intracerebral arteries, and may be due to an age-related dysfunction in the blood-brain-
barrier (BBB) that leads to impaired clearance of Aβ from the brain, further confounding 
the accumulation of Aβ in aging brains (Greenberg et al., 2004; Zlokovic, 2008).  
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CAA can result in cognitive impairment as it causes hypoperfusion by narrowing 
the vessels (Farkas and Luiten, 2001; Smith and Greenberg, 2009; Fossati et al., 2012); 
increased vulnerability to ischemic injury by reducing vascular reactivity and 
compromising the structural integrity of microvessels (Zhang et al., 1997); and increased 
prevalence of small hemorrhages or microbleeds, causing ischemia (Smith and 
Greenberg, 2009; Armstrong, 2006; Jiwa et al., 2010). Interestingly, severe cerebral 
hemorrhages are characteristic of the FAD Dutch E22Q Aβ variant (Fossati et al., 2012). 
CAA is also associated with cerebral atherosclerosis, an identified risk factor for 
developing AD (de le Torre, 2002; Aliev et al., 2002). Microvessels damaged by CAA 
demonstrate co-localization of Aβ and oxidative stress markers (Aliev et al., 2002) as 
well as inflammatory pathology (Dermaut et al., 2001), all key pathogenic factors in 
neurovascular dysfunction in AD and other neurodegenerative disorders such as stroke 
(Iadecola, 2010).  
1.7 Neuroinflammation 
Chronic inflammation - marked by microgliosis, astrocytosis, and the release of 
pro-inflammatory cytokines - is a hallmark of AD brains, but it is not clear if 
inflammation is the primary cause in initiating AD (Humpel, 2011) or a result of Aβ 
dysregulation (Moore and O’Banion, 2002). Regardless, inflammation is a major factor 
implicated in neurodegeneration in AD and aging, and is known to enhance oxidative 
stress (Humpel, 2011) by up-regulating the expression of free-radical producing enzymes 
and down-regulating anti-oxidant defenses (Iadecola, 2010), which can accelerate 
neuronal death and the progression of AD (Herrup, 2010; Koistinaho and Koistinaho, 
2005; Peila and Launer, 2006). 
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Chronic neuroinflammation also leads to an increase in Aβ expression and 
deposition (Goldgaber et al., 1989; Ge and Lahiri, 2002), as the amyloid deposition cycle 
(Herrup, 2010) illustrates the intimate relationship between inflammation and AD 
pathology: Aβ aggregates trigger a cytokine-mediated immune response, which 
stimulates Aβ production and further inflammatory cell recruitment. Most amyloid 
plaques are intimately associated with activated astrocytes and “frustrated microglia” 
attempting to clear the plaques, however microglia are believed to play an important role 
in plaque formation (Eikelenboom et al., 1994; Griffin et al., 1995). Activated microglia 
secrete cytotoxins (including cox-2 and complement) and cytokines (TNF and IL-1) 
(Benveniste, 1995; Giulian, 1995) in an attempt to destroy the plaques and attract other 
inflammatory cells. Inadvertantly this can aggravate APP expression and Aβ generation 
(Benveniste, 1995; Giulian, 1995) as well as cause neuronal death through “bystander 
lysis” (Sheng et al., 2003), further perpetuating the neuroinflammatory response.  
Retrospective studies found that the long-term use of non-steroidal anti-
inflammatory drugs (NSAIDs) lowered the risk of AD by 30-60% (McGeer et al., 1996; 
Stewart et al., 1997; Vlad et al., 2008) and many hypothesized that anti-inflammatory 
drugs may be used to delay AD (Perry et al., 1995; Moore and O’Banion, 2002). Anti-
inflammatories, including NSAIDs, have failed at preventing disease progression in 
clinical trials (Van Gool et al., 2001) and some have even been detrimental (ADAPT, 
2008) likely because the disease process is too far advanced when the treatment begins 
(Herrup, 2010), and due to the fact that inflammation is one of the natural healing 
responses of the brain.  
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While AD transgenic mice fail to demonstrate neurodegeneration, they do show 
Aβ plaque formation and neuroinflammation and thus are said to model early AD 
(Benilova et al., 2012; Abramowski et al., 2012). Transgenic mice overexpressing APP 
demonstrated enhanced sensitivity to lipopolysaccharide (LPS)-induced inflammation 
(Sheng et al., 2003) and a heightened vulnerability to ischemic injury (Zhang et al., 1997; 
Koistinaho et al., 2001; Whitehead et al., 2010), resulting in greater neurodegeneration 
due to potentiation of the neuroinflammatory response. The enhanced neuroinflammation 
was associated with increased expression of APP and accumulation of Aβ, implicating 
inflammation as an etiological factor in AD by inducing excessive generation and 
precipitation of Aβ species (Sheng, 2003). Aβ is not only capable of precipitating AD, it 
can also act as a pathogenic substrate by potentiating the neuroinflammatory effects of 
secondary insults (Pike et al., 1995; Herrup, 2010). 
1.8 Stroke 
Stroke is an interruption in the blood supply to the brain causing ischemia and is a 
major cause of death and disability in industrialized nations (Lai et al., 2011). Subclinical, 
or ‘silent’, strokes are the most common type of stroke and their prevalence increases 
rapidly with increasing age (Hachinski, 2008; Vermeer et al., 2003). Depending on the 
location of the stroke and the rate and duration of ischemic conditions, stroke can cause 
massive cell death mediated by both necrotic and apoptotic pathways (Gabryel et al., 
2012). Necrosis occurs when cells are exposed to acute stress or energy depletion, 
causing cellular swelling, edema and damage to neighbouring tissues inducing an 
inflammatory response (Gabryel et al., 2012; Yamashima and Oikawa, 2009). The core of 
the infarct is marked by necrotic cell death, as it is directly subjected to hypoxia and the 
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effects of deleterious agents released from adjacent cells (Obrenovitch, 1995). The acute 
neuroinflammatory response is marked by the adhesion and extravasation of leukocytes 
and the activation, proliferation and migration of microglia to the site of damage (Bruce-
Keller, 1999, Stoll et al., 1998; Marks et al., 2001) where they can inadvertantly 
aggravate damage caused by the primary ischemic insult (Dirnagl et al., 1999). 
Apoptosis is the prototypical form of cell death in the peri-infarct region, or 
penumbra, where neurons are less affected by reduced oxygen and nutrient supply, and is 
not accompanied by an inflammatory response or surrounding tissue damage (Taoufik 
and Probert, 2008). Excluding stress proteins such as heat shock protein 70 (HSP70) and 
apoptotic elements, protein synthesis is reduced in the penumbra and is one of the earliest 
and most sensitive metabolic consequences of ischemia (Rebel et al., 2005).  
1.9 The Ischemic Cascade: Glutamate Toxicity 
The ischemic cascade is a series of biochemical events initiated within seconds 
after the infarction occurs that results in the propagation of irreversible tissue damage to 
the periphery of the infarct (Gabryel et al., 2012). The primary mechanism mediating 
stroke damage is glutamate receptor over-activation, caused by the uncontrolled release 
and extracellular accumulation of glutamate, the primary excitatory neurotransmitter in 
the mammalian CNS, causing excitotoxicity and neuronal death (Reviewed Lai et al., 
2011; Lee et al., 1999; Rothman and Olney, 1995; Simon et al., 1984; Traynelis et al., 
2010; Ryan et al., 2008; Yamashima and Oikawa, 2009; Hossman, 1996). Glutamate 
receptor over-activation leads to a Ca2+ influx into the cell, disrupting normal Ca2+ 
homeostasis and mitochondrial function, causing a massive increase in production of 
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reactive oxygen species (ROS) (Yamashima and Oikawa, 2009). ROS are formed by the 
partial reduction of oxygen, and can induce extensive damage to DNA, lipids, proteins 
and lysosomal membranes, collectively termed oxidative stress (Yamashima and Oikawa, 
2009). The brain is particularly vulnerable to oxidative stress because it is the most lipid-
rich organ in the body, consumes a large percentage of the total inspired oxygen and has a 
relative lack of anti-oxidant defense enzymes (Coyle and Puttfarcken, 1993; Yamashima 
and Oikawa, 2009). This susceptibility to oxidative stress results in secondary 
neurodegeneration in the penumbra and subsequent expansion of the infarct (Delivoria-
Papadopoulus and Mishra, 2000; Leon et al., 1991; Kogure and Kogure, 1997; Samdani, 
Dawson and Dawson, 1997). Blocking glutamate receptors to prevent excitotoxicity has 
shown to exacerbate stroke outcomes (Lai et al., 2011) likely because glutamate receptors 
mediate many different neuronal functions and cannot be blocked non-specifically 
without some undesired effects, making it necessary to find therapeutic targets 
downstream of glutamate receptor activation.  
1.10 Autophagy in Stroke 
Stroke exposes neurons to a variety of different cellular stress factors and all of 
which are capable of initiating autophagy, a mechanism to help cells adapt to stress by 
generating metabolic substrates (Kubota et al., 2010). Autophagy has shown to be 
protective following serum deprivation in neurons, as well as in animal models of 
neonatal hypoxic/ischemic injury, and cerebral injury such as traumatic brain injury 
(TBI) (Carloni, Buonocore and Balduini, 2008; Erlich et al., 2007; Steiger-Barraissoul 
and Rami, 2009). However, the excessive activation of autophagy following cerebral 
ischemia has shown to mediate neuronal death in the infarct (Koike et al., 2008; Rami et 
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al., 2008; Wen et al., 2008; Puyal et al., 2009), and inhibiting autophagy suppressed 
neuronal death in in vivo models of ischemia (Kubota et al., 2005; Samara, Syntichaki 
and Tavernarakis, 2008; Wen et al., 2008).  
Apart from complete cellular atrophy, excessive autophagic activity is believed to 
partially mediate cell injury during ischemia due to the ROS-generating activity of 
autophagic cellular machinery such as autophagosomes and lysosomes, as well as 
mitochondria (Kubota et al., 2005). The constitutive levels of ROS produced in cells by 
mitochondria and lysosomes may explain cell-susceptibility to glutamate-induced 
oxidative cytotoxicity (Kubota et al., 2005), as autophagy and lysosome inhibitors were 
both able to diminish glutamate-induced toxicity in vitro, as well as attenuate neural cell 
death and reduce infarct volume following ischemia in rats (Kubota et al.,2005; Gabryel 
et al., 2012; Puyal et al., 2009). 
1.11 Stroke and AD   
Strong epidemiological evidence exists that vascular risk factors are involved in 
the pathogenesis of AD (Reviewed by Iadecola, 2010; Cechetto et al., 2008) as studies 
indicate that AD and stroke not only share common risk factors including age, 
hypertension, atherosclerosis and diabetes (Reviewed by Iadecola, 2010) but that stroke 
itself greatly increases the risk of developing AD (Kalaria, 2009; Sonnen et al., 2009; 
Vermeer et al., 2003; Ballard et al., 2000; Esiri et al., 1999). The prevalence of dementia 
is higher in ischemic stroke patients than controls (Kalaria, 2002; Tatemichi et al., 1992), 
and importantly more than half develop progressive dementia – such as AD – where the 
cerebral damage is not a direct cause of the subsequent dementia, as it is in vascular 
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cognitive impairment (VCI) (Tatemichi et al., 1994; Gearing et al., 1995; Hachinski, 
2008). Stroke can lead to VCI depending on the location of the infarct, or as a result of 
progressive neuronal loss as evidenced in multi-infarct dementia (Hachinski et al., 1974). 
AD is the most common cause of senile dementia, and with VCI makes up 75% of cases 
of senile dementia (Gearing et al., 1995; Hachinksi, 2008; Humpel, 2011; Wang et al., 
2010). AD can be difficult to differentiate from VCI, as stroke is the most common 
comorbidity with AD as approximately 40% of AD patients present with vascular 
pathology at autopsy, the majority of which are subcortical lacunar infarcts, or small 
striatal strokes (Jellinger, 2008; Gearing et al., 1995; Kalaria, 2000; Heyman, 1998; 
Snowdon et al., 1997). Remarkably, the coexistence of small striatal strokes in patients 
with even moderate Aβ deposition had a profound effect on the severity of the dementia, 
compared to patients with equivalent Aβ pathology alone (Nagy et al., 1997; Heyman et 
al., 1998; Snowdon et al., 1997; Hachinski, 2008; Humpel, 2011; Whitehead et al., 
2005a).  
1.12 A Comorbid Condition: Underlying Mechanisms and Overlapping Pathologies 
Based on their co-morbidity and the pathological significance of their interaction, 
it is imperative to study stroke and AD in a clinically relevant co-morbid animal model. 
The common vascular risk factors and high comorbidity between stroke and AD indicate 
related pathogenic mechanisms (De la Torre, 2002), which may explain their complex 
synergistic relationship and guide new therapeutic strategies. Modeling the brain at risk 
for developing dementia – where striatal stroke occurs in the presence of Aβ (Whitehead 
et al., 2005a,b, 2007a) – also allows the testing of therapeutics in a preventative approach, 
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as it is difficult to define AD onset as it has such a long pre-symptomatic phase (Sperling 
et al., 2011; Perrin, Fagan and Holtzman, 2009). 
1.13 Aβ and Stroke: AD Correlates 
Stroke has shown to result in the generation of AD correlates - specifically 
increased APP expression, Aβ generation and accumulation of hyperphosphorylated tau - 
which is believed to be one way in which stroke accelerates AD progression (Kalaria et 
al., 1993; Wang et al., 2010; Iadecola, 2004). It is worth noting that excessive synaptic 
activity due to epilepsy or excitotoxic injury can enhance Aβ production (Herrup, 2010); 
traumatic brain injury (TBI) can cause an up-regulation in APP, Aβ, β-secretase and 
PSEN1 expression which largely determines the extent of the injury (Loane et al., 2009); 
and LPS-induced inflammation also enhances APP expression and Aβ generation (Sheng 
et al., 2003), so it is not necessarily the nature of the injury, but of the response (Herrup, 
2010) that may precipitate AD if it occurs in the vulnerable brain. 
The generation of Aβ following ischemia is directly correlated with secondary 
neuronal loss (Zhang et al., 2010, 2011), as β-secretase activity is elevated - favouring 
amyloidogenic processing of APP (Hiltunen et al., 2009) - and inhibiting Aβ production 
with a γ-secretase inhibitor improved neuronal survival following stroke (Zhang et al., 
2011). Autophagy is an active pathway for Aβ production (Yu et al., 2005), and has been 
shown to contribute to neuronal death following ischemia (Nixon, 2007). Inhibiting 
autophagy has shown to reduce neuronal loss following stroke by reducing generation of 
ROS (Kubota et al., 2010), and more recently it was shown that autophagy inhibitors 
reduce β-secretase levels, inhibiting generation of Aβ and improving neuronal survival 
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(Zhang et al., 2012). Thus, as we identify other pathological points of overlap we gain 
new therapeutic strategies and targets. 
1.14 Aβ and Stroke: Inflammation  
Early co-morbid animal models used transgenic mice over-expressing APP that 
were subjected to middle cerebral artery occlusion (MCAO), and discovered that the 
complex pathological relationship between stroke and Aβ is bidirectional: Aβ toxicity 
enhanced stroke pathology resulting in enhanced neuroinflammation, increased infarct 
volume and greater neuronal loss (Zhang et al., 1997; Koistinaho et al., 2001). Aβ 
toxicity is believed to enhance the effects of secondary insults primarily through 
potentiation of the neuroinflammatory response (Sheng et al., 2003; Whitehead et al., 
2005a,b, 2007a; Zhang et al., 1997; Koistinaho et al., 2001; Hiltunen et al., 2009; Lai et 
al., 2011), which is also believed to underlie the stroke-induced aggravation of cognitive 
impairment (Li et al., 2011).  
To improve the validity and clinical relevancy of this work, our lab established a 
model employing small striatal infarcts, as they showed the highest correlation with 
magnifying the cognitive impairment induced by Aβ toxicity (Snowdon et al., 1997; 
Heyman et al., 1998). To control the age and extent of Aβ toxicity, we developed an Aβ-
infusion model to induce generalized Aβ toxicity via bilateral intracerebroventricular 
(i.c.v.) injection of Aβ25-35, and have recapitulated the clinical phenomena: small striatal 
strokes were able to enhance the effects of Aβ on cognitive impairment, and Aβ led to an 
enhanced neuroinflammatory response following stroke resulting in a progressive 
increase in infarct size and AD correlates (Whitehead et al. 2005a, 2007a; Cheng et al., 
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2006). Targeting the neuroinflammatory response with a variety of anti-inflammatories 
has typically shown benefit for either pathology in isolation, yet when combined anti-
inflammatories are much less effective at ameliorating the resulting pathology 
(Whitehead et al., 2005b, 2010). Thus it is important to identify other points of 
pathological overlap the co-morbid condition in order to guide therapeutic strategies to 
complement anti-inflammatory treatment. 
1.15 Ganglioside Biochemistry 
Gangliosides - complex sialic acid-containing glycosphingolipids - are 
differentially expressed in all vertebrate cells and are particularly enriched in the brain 
where they have regulatory roles in many physiological processes including nerve growth 
and differentiation, synaptogenesis, cell signaling, neuronal plasticity and the modulation 
of immune responses and cell death and survival processes (Svennerholm, 1994; Bektas 
and Spiegel, 2004; Ledeen and Wu, 2004; Nakatsuji & Miller, 2001; Riboni et al., 1997). 
Gangliosides are typically found in the outer cell leaflet of the plasma membrane where 
they act as the functional lipid component of membrane lipid rafts (Kreutz et al., 2011). 
Gangliosides are anchored into the plasma membrane by a ceramide moiety, with an 
oligosaccharide tail extending into the extracellular environment that is differentially 
modified by the addition of sialic acid residues (Wu et al., 2005; Malisan & Testi, 2002) 
that contribute to the charge, physicochemical properties and functional implications of 
gangliosides (Schauer, 1985; Riboni et al, 1995).  
Gangliosides have been implicated in cell death and cell survival processes (Sohn 
et al., 2006; Kreutz et al., 2011), and it is believed that they may play an important role in 
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determining the neuronal response to injury due to their roles in the maintenance and 
repair of nervous tissue (Furukawa et al., 2007; Kittaka et al., 2008) as well as their 
regulation of cell proliferation and cell death (Giammarioli et al., 2001; De Maria et al., 
1997). Their diverse glycan structures extend into the extracellular space and function in 
cell-cell recognition and as receptors or co-receptors for many ligands such as cytokines, 
toxins, hormones and viruses (Bergelson, 1995), and through their lateral association with 
signaling molecules in the plasma membrane gangliosides can impact global cellular 
events (Lopez and Schnaar, 2009). 
Gangliosides are also found in blood plasma and the cerebrospinal fluid (CSF), 
and there is a constant exchange between cell-associated and non-cell-associated 
gangliosides meaning they can be ‘shed’ from the cell surface into the extracellular space 
during cell membrane turnover, and exogenous gangliosides can be incorporated back 
into the plasma membrane (Malisan & Testi, 2002; Bergelson, 1995). Degenerative 
processes in the CNS are associated with an increased shedding of membrane fragments, 
as cellular degeneration leads to an increased turnover of cell membranes and subsequent 
release of gangliosides (Miyatani et al., 1990; Trbojevic-Cepe et al., 1991; Tarvonen-
Schroder et al., 1997; Andersson et al., 1998).  
1.16 Ganglioside Expression and Synthesis 
Ganglioside biosynthesis occurs in a step-wise manner beginning in the early 
Golgi apparatus with the glycosylation of ceramide (Malisan & Testi, 2002; Daniotti and 
Bartolome, 2011) (Fig. 1a). GM3 is the simplest ganglioside and is the common 
precursor for ganglioside biosynthesis (Ju et al., 2005). Through the sequential addition 
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Figure 1 - Ganglioside metabolism. Ganglioside expression is a dynamic process with 
regulatory roles in the differentiation, development and repair of CNS tissue. A) 
Biosynthesis occurs along the secretory pathway, starting with the glycolysis of ceramide, 
followed by the sequential addition of sugar residues and sialic acid residues resulting in 
a high diversity of final products expressed in the outer cell membrane or released into 
the extracellular space. B) Catabolism is an endocytosis- and lysosome-dependent 
process, generating partial or full degradation products that are recycled for ganglioside 
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of carbohydrates and sialic acid residues to GM3, with each step regulated by specific 
membrane-bound glycosyltransferases, cells can generate the a-, b- and c- series of 
gangliosides (Malisan & Testi, 2002) (Fig.1a). 
It is established that ganglioside expression is a dynamic process, representing a 
cell’s adaptation to environmental conditions with expression profiles changing 
drastically during development, the cell cycle, differentiation and disease (Nagai, 1995; 
Nakatsuji & Miller, 2001; Svennerholm, 1980; Vyas and Schnaar, 2001; Mocchetti, 
2005; Lopez and Schnaar, 2009; Yu et al., 2012). The embryonic vertebrate brain is 
characterized by an abundance of simple gangliosides such as GM3 and GD3 
(Stojiljkovic et al., 1996; Yu et al., 1988; Ju et al., 2005), while at later developmental 
stages complex gangliosides dominate, specifically the major brain gangliosides GM1, 
GD1a, GD1b and GT1b (Reviewed by Yu et al., 2012). GM3 is typically below detection 
threshold in the healthy adult mouse (Whitehead et al., 2011) and human brain (Marconi 
et al., 2005).  
Studies investigating the in situ expression of gangliosides in normal and 
pathologic CNS conditions often demonstrate conflicting results with in vitro studies, as 
culture conditions may modulate the biological properties of cells, in particular the 
expression of glycolipids (Marconi et al., 2005; Kawai et al., 1999; Nardelli et al., 1994). 
Marconi et al. (2005) demonstrated that in the post-mortem brains of adult humans who 
died of both non-neurological diseases and neurological diseases (progressive multiple 
sclerosis, AD, amyotropic lateral sclerosis and stroke) GFAP-positive astrocytes 
expressed GM1, GD1b and GD3, which is a minor ganglioside in most tissues but is  
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highly expressed in the placenta and thymus, while reactive microglia were GD1a 
positive; however neither astrocytes nor microglia expressed GM3. 
1.17 Ganglioside Catabolism 
Ganglioside catabolism is an endocytosis- and lysosome-dependent process that 
generates degradation products to be recycled throughout the cell for biosynthesis 
(Malisan & Testi, 2002; Pitto et al., 2004) (Fig. 1b). The catabolism pathway is the same 
for cell-associated and non-cell associated gangliosides, however non-cell associated 
gangliosides must first be incorporated into the plasma membrane; from there complex 
gangliosides undergo endocytosis and are delivered mainly to lysosomes where 
degradation occurs (Pitto et al., 2004). Similar to ganglioside synthesis, catabolism is a 
step-wise process where sialic acid and sugar residues are sequentially removed by 
specific enzymes (Sandhoff and Kolter, 2003; Miyagi et al., 1999). Partial degradation 
products can be routed out of lysosomes into salvage pathways directly for ganglioside 
biosynthesis, or undergo complete degradation in the lysosomes where end products, such 
as sphingosine, can be recycled for synthesis of other biomolecules such as 
sphingomyelin (Riboni et al., 1991; Malisan & Testi, 2002; Tettamanti, 2004; Kolter and 
Sandhoff, 2010; Sandhoff and Kolter, 2003; Tettamanti et al., 2003). In slowly dividing 
cells the recycling pathway is predominant, while rapidly dividing cells favour the de 
novo synthesis of gangliosides (Gillard et al., 1998). 
Complex gangliosides in the CNS are first degraded to GM1 by the sequential 
removal of sialic acid residues by a membrane-bound sialidase (Miyagi et al., 1999; 
Prokazova et al., 2009; Ledeen, 1990; Furst and Sandhoff, 1992), which can occur 
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outside of the lysosome at the plasma membrane (Riboni et al., 1995). Further 
degradation beyond GM1 is lysosome dependent, where the lysosomal glycosidase β-
galactosidase degrades GM1 to GM2, and GM2 to GM3, before the final sialic acid 
residue can be removed (Van Echten and Sandhoff, 1993; Sandhoff and Kolter, 2003; 
Riboni et al., 1995). Inhibiting endocytosis with low temperatures, or lysosomal activity 
with Chloroquine - a lysomotropic agent that raises lysosomal pH - prevents the 
appearance of GM3 as well as formation of any degradation products downstream of 
GM1 (Fig. 1b) (Riboni et al., 1995).  
1.18 Defects in Gangioside Metabolism 
Genetic defects in ganglioside metabolism can lead to severe complications and 
disease, however the majority of human diseases associated with ganglioside metabolism 
are caused by defects in catabolism; human diseases associated with impaired ganglioside 
synthesis are much rarer (Simpson et al., 2004; Dawkins et al., 2001). 
In genetically altered mice that lack the ability to synthesize complex gangliosides 
(GalNac-T KO) or their precursors (GlcCer-T KO), it has been demonstrated that 
gangliosides are essential for embryonic development (Yamashita et al., 1999) and that 
complex gangliosides play an important role in the maintenance and repair of nervous 
tissue, evidenced by neurodegenerative changes after birth (Furukawa et al., 2007; 
Yamashita et al., 1999; Ohmi et al., 2011; Jennemann et al., 2005). GalNac-T KO mice 
displayed normal brain morphology at birth, but impaired intracellular Ca2+ homeostasis 
led to increased neuronal susceptibility to apoptosis along with CNS impairment, 
neurodegeneration and shorter lifespans (Wu et al., 2001; Chen et al., 2005; Furukawa et 
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al., 2007; Yamashita et al., 1999; Takamiya et al.,1996; Sheikh et al., 1999; Wu et al., 
2005). 
 The mechanisms behind the degenerative changes in these genetically altered 
mice are not entirely clear, but evidence suggests complex gangliosides regulate Ca2+ 
homeostasis (explaining the increased susceptibility to apoptosis) (Wu et al., 2004; Wu et 
al., 2005; Wu et al., 2001) and activation of the complement system by maintaining lipid 
raft integrity (Furukawa et al., 2011; Okada et al., 2002). Neurodegeneration is likely 
confounded in these genetically altered mice based on the finding that complex 
gangliosides also play a role in the ability of astrocytes to support neuronal survival 
(Akasako et al., 2011). Cultured astrocytes that were treated with d-1-phenyl-2-
decanoylamino-3-morpholino-1-propanol (d-PDMP), a synthetic ceramide analogue that 
inhibits glucosylceramide synthesis (Fig. 1b) and depletes all endogenous gangliosides 
(Inokuchi et al., 1989; Inokuchi and Radin, 1987), showed reduced capacity to support 
neuronal survival (Akasako et al., 2011). d-PDMP was also shown to inhibit functional 
synapse formation and reduce neurite outgrowth in cultured neurons from wild-type rats, 
indicating that complex gangliosides are important for proper CNS functioning (Mizutani 
et al., 1996; Inokuchi et al., 1997; Harel and Futerman, 1993).       
1.19 Lysosomal Storage Diseases 
The impaired ability to degrade gangliosides leads to the accumulation of 
gangliosides and secondary metabolites (Walkley, 2004) - such as cholesterol (Lloyd-
Evans and Platt, 2010) – within endosomal or lysosomal compartments, and is 
characteristic of severe conditions known collectively as lysosomal storage diseases 
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(LSDs) which can result in cognitive impairments and early lethality (Patschan et al., 
2008; Vitner et al., 2010; Kolter and Sandhoff, 2010; Sandhoff and Kolter, 2003; Marks 
and Pagano, 2002; Schuette et al., 1999). LSDs can be due to inherited genetic defects in 
enzymes responsible for the degradation of gangliosides, such as β-galactosidase which 
results in the accumulation of GM1 (GM1 gangliosidosis) (Vitner et al., 2010), or in 
cholesterol trafficking defects downstream of impaired lysosomal functioning as in 
Niemann Pick C disease (Lloyd-Evans et al., 2008) which also leads to the accumulation 
of gangliosides (Vitner et al., 2010). The accumulation of gangliosides within endosomal 
compartments initiates an inflammatory response in both the periphery and the CNS, and 
inflammation often precedes the onset of other symptoms (Jeyakumar et al., 2003). In 
addition to inflammation, GM1 gangliosidosis also displays oxidative stress, endoplasmic 
reticulum (ER) stress, altered calcium homeostasis, autophagy and altered lipid 
trafficking (Reviewed by Vitner et al., 2010).  
Reduced proteolytic activity associated with aging can also lead to the 
accumulation of gangliosides, a process that is associated with cell senescence that can 
activate apoptosis (Kurz et al., 2000; Malisan and Testi, 2002; Sano et al., 2009). In this 
regard, AD resembles an adult-onset lysosomal storage disease (Pasternak et al., 2003), 
as cells lose the ability to efficiently degrade Aβ and hyperphosphorylated tau, which 
eventually reach neurotoxic concentrations both inside and outside of the cell (Daniotti 
and Bartolome, 2011). 
Interestingly, the enantiomeric form of d-PDMP, l-PDMP, has been shown to 
increase the biosynthesis of gangliosides (Inokuchi et al., 1989,1995) by up-regulating 
glucosylceramide synthesis, which is responsible for ganglioside biosynthesis (Inokuchi, 
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2009). Adding l-PDMP to cultured neurons resulted in functional synapse formation 
(Inokuchi et al., 1997) and stimulated neurite outgrowth (Usuki et al., 1996) showing it 
was possible to augment normal levels of gangliosides in neurons and thereby produce 
beneficial effects (Inokuchi et al., 1997).  
It’s been demonstrated that ischemia reduces ganglioside levels (Rastogi et al., 
1968; Domanska-Janik et al., 1982; Qi and Xue, 1991; Ramirez et al., 2003), and l-
PDMP was effective at ameliorating the spatial memory deficit induced by MCAO in rats 
(Inokuchi et al., 1997; Yamagishi, 2003) and prevented apoptosis in the hippocampus, 
even when administered 24 hours after ischemia (Inokuchi, 2009). L-PDMP is believed 
to improve neurological outcome following stroke by increasing ganglioside 
biosynthesis, as gangliosides promote neurite outgrowth and recovery (Inokuchi et al., 
1997; Yamagishi et al., 2003; Usuki et al., 1996; Iwasaki et al., 1998). Exogenous 
gangliosides can also elicit neurite outgrowth and neural repair in vitro and in vivo (Pepeu 
et al, 1994; Tsuji et al., 1992; Wu et al, 1991) as well as attenuate serum-deprivation 
induced neuronal apoptosis (Ryu et al., 1999). It is important to note that gangliosides do 
not function as neurotrophic factors themselves, but act by potentiating neurotrophic 
influences present in the CNS (Ariga et al., 2010).  
1.20 GM1 and GD1b Mediate Prosurvival Processes 
GM1 is one of the major brain gangliosides and has demonstrated neuroprotective 
as well as neurotrophic effects in a variety of paradigms (Yu et al., 2009). GM1 has been 
shown to potentiate neurotrophin release and action, exert anti-oxidant effects, modulate 
signaling pathways involved in death processes, and dose-dependently reduce glutamate-
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induced excitotoxicity in vitro and in vivo (Yu et al., 2009; Rabin et al., 2002; Mocchetti, 
2005; Fighera et al., 2004; Furian et al., 2007; Gavella et al., 2007; Cunha et al, 1999; 
Mutoh et al., 1995; Pitto et al., 1998; Lili et al., 2005; Carolei et al., 1991; Fusco et al. 
1993; Leon et al., 1991). GM1 effectively decreased the severity of ischemic brain 
lesions in experimental models (Frontczak-Baniewicz et al, 2000; Hicks et al, 1998; 
Yamagishi et al., 2003), and while its mechanism is not clear, GM1 works downstream of 
glutamate receptor over-activation and is related solely to the limitation of intracellular 
events (Carolei et al., 1991; Daniotti & Bartolome, 2011).  
GM1 showed therapeutic promise as its systemic administration could not only 
effectively reduce acute neuronal damage by attenuating excitotoxicity, but could also 
facilitate long-term functional recovery after brain injury by potentiating the effects of 
neuronotrophic factors (Carolei et al., 1991; Daniotti & Bartolome, 2011), which led 
some to postulate that GM1 may be effective in treating AD (Biraboneye et al, 2009). 
GM1 proved less effective in human studies however, as it was tested in over 2000 
patients across twelve trials for stroke and showed no functional benefit (Candelise and 
Ciccone, 2002), as well as potential aversive side effects as anti-GM1 antibodies are 
associated with the neurological disorder Guillan-Barre Syndrome (Nores et al., 2008; 
Willison and Yuki, 2002; Zhang and Kiechle, 2004).  
The predominant expression of b-series gangliosides - of which GD1b belongs - 
was shown to reduce ceramide-induced apoptosis (Bieberich et al., 2001). Excessive K+ 
efflux promotes apoptosis in almost all cell types (Hribar et al., 2004) and neurons 
(Reviewed by Chen et al., 2005), and K+ channel blockers have been shown to be able to 
suppress apoptosis (Yu, Canzoniero and Choi, 2001; Yu et al., 1997). After exogenous 
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administration of the major brain gangliosides, GD1b was the only ganglioside capable of 
suppressing staurosproine-induced apoptosis by inhibiting K+ efflux (IK) (Chen et al., 
2005).  
1.21 Gangliosides Affect Aβ Fibrillization and Expression 
The fibrillization of amyloid is believed to be a key step in the pathogenesis of 
AD (Yu et al., 2012; Yanagisawa et al., 1995; Yanagisawa and Ihara, 1998; Hayashi et 
al., 2004) and appears to be mediated by gangliosides. Ganglioside-bound Aβ (GAβ) was 
first discovered in brains with early pathological AD changes (Yanagisawa et al., 1995) 
and led to the GAβ hypothesis: Aβ binds to ganglioside clusters on neuronal membranes 
forming GAβ, which alters the conformation of Aβ and acts as an endogenous seed in the 
brain facilitating amyloid fibril formation from soluble Aβ species (Yangaisawa et al., 
2005, 2011). The formation of unique ganglioside clusters that induce GAβ formation are 
likely influenced by risk factors for AD, specifically aging and ApoE4 (Yamamoto et al., 
2004), and facilitated by endocytic pathway abnormalities observed in AD brains 
(Cataldo et al., 2000; Yuyama et al., 2006, 2008; Yuyama & Yanagisawa, 2009). GM1 is 
able to bind Aβ (Yanagisawa et al, 1995; Wakabayashi et al., 2005; Okada et al., 2007) 
and among all of the major brain gangliosides, demonstrates the greatest seeding 
potential, or ability to induce fibrillization of Aβ (Yanagisawa, 2011). GM1 is present in 
amyloid plaques bound specifically to Aβ (Yanagisawa et al. 1995; Yanagisawa and 
Ihara, 1998).  
One experiment demonstrated that exogenous GM1 reduced plaque load in the 
brains of APP transgenic mice, however this is likely a result of GM1 sequestering 
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peripheral Aβ (Matsuoka et al., 2003), as the exogenous administration of GM1 to cells 
overexpressing APP has shown to drastically increase Aβ secretion while attenuating 
sAPPα secretion (Tamboli et al., 2008; Grimm et al., 2012; Zha et al., 2004). d-PDMP 
was able to reduce secretion of Aβ, which was reversed by the addition of exogenous 
gangliosides (Tamboli et al., 2005). It is suggested that gangliosides are involved in the 
subcellular transport of APP, and hence affect its proteolytic processing (Tamboli et al., 
2005, 2008). Double transgenic mice expressing APP and PSEN1 mutations exhibit 
memory impairments and Aβ pathology, while triple transgenic mice expressing the same 
AD mutations, but also lacking GD3 synthase and therefore complex b-series 
gangliosides, perform as well as wildtype mice and the Aβ pathology and behavioural 
impairments are almost completely eliminated (Bernardo et al., 2009). The mechanism is 
far from clear how altered ganglioside biosynthesis leads to the elimination of Aβ. 
1.22 GM3 
GM3 is the simplest ganglioside and the common precursor for ganglioside 
biosynthesis, however it is normally only expressed in the brain during embryonic 
development and is below detection threshold in the healthy adult mouse (Whitehead et 
al., 2011) and adult brain (Ju et al., 2005; Stojilikovic et al. 1996; Marconi et al., 2005). 
GM3 is the major serum ganglioside however, and is highly expressed in endothelial cells 
where it has been shown to inhibit angiogenesis in vivo (Lopez & Schnaar, 2009), 
suggesting a regulatory role. GM3 is used as a serum biomarker of metabolic syndrome, 
as it correlates with LDL cholesterol levels (Inokuchi, 2011) and is an inducer of insulin 
resistance (Ryden and Arner, 2007). Diabetes mellitus, or type 2 diabetes, is a major risk 
factor for stroke that also increases AD morbidity (Iadecola, 2010), and has been re-
	   	   	   	   	  
	  31	  
envisioned as a membrane microdisorder caused by the aberrant expression of 
gangliosides, specifically GM3 (Inokuchi, 2011). Elevated GM3 concentrations in the 
cerebrospinal fluid (CSF) correlate with BBB dysfunction, and may be an indicator of 
cerebral hemorrhage, compressive syndromes or brain melanoma (Trbojevic-Cepe et al., 
1991). Once again, degenerative processes in the CNS lead to the increased shedding of 
membrane fragments and gangliosides into the intercellular space (Miyatani et al., 1990; 
Trbojevic-Cepe et al., 1991; Tarvonen-Schroder et al., 1997; Andersson et al., 1998; 
Malisan and Testi, 2002). GM3 is also the major ganglioside in monocytes and 
lymphocytes (Kiguchi et al., 1990) and is believed to control differentiation of peripheral 
monocytes into macrophages - a critical process in the development of the inflammatory 
reaction (Gracheva et al., 2009) – as GM3 is enhanced in atherosclerotic lesions 
(Bobryshev et al., 1997). GM3 expression can be influenced by inflammatory cytokines 
(Inokuchi, 2011) as tumour necrosis factor α (TNFα) – a multifunctional cytokine with a 
well-established role in inflammation (Prokazova et al., 2009) - increases expression of 
GM3 in adipocytes, and TNFα-induced insulin resistance was prevented by decreasing 
GM3 levels with d-PDMP (Inokuchi et al., 2011). While the relationship is not fully 
understood, GM3 is also believed to be involved in the regulation of TNFα expression 
(Prokazova et al., 2009). 
GM3 is being investigated as a potential anti-tumour therapy as it has shown the 
ability to prevent angiogenesis in vivo (Lopez & Schnaar, 2009) and has effectively been 
shown to inhibit cell proliferation and induce apoptosis (Nagata, 1996; Nachbur et al., 
2006) in human brain tumours and gliomas (Nakatsuji & Miller, 2001; Nakamura et al., 
1991). Since exogenous gangliosides can be incorporated into the plasma membrane and 
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internalized by endocytosis to be degraded and recycled throughout the cell (Malisan & 
Testi, 2002), it was believed that GM3 induced apoptosis through ceramide, a 
degradation product of GM3 that is involved in growth suppression and apoptosis (Obeid 
et al., 1993; Pushkareva, Obeid and Hannun, 1995). An inhibitor of lysosomal 
glucocerebrosidase, conduritol beta-epoxide (CBE), which prevents the conversion of 
glycosylceramide to ceramide, however did not prevent the GM3-induced apoptosis and 
inhibition of proliferation (Schwarz et al., 1995), suggesting GM3 induces apoptosis 
through a separate mechanism.  
1.23 GM3: Tombstone or Trigger? 
The role of GM3 in cell death was initially unclear, as several groups 
demonstrated that neurons undergoing apoptosis or glutamate toxicity increased GM3 
expression (Ju et al., 2005; Sohn et al., 2006; Kreutz et al., 2011) and that GM3 
accumulates in stroke and AD brains (Kracun et al., 1991; Kwak et al., 2005; Whitehead 
et al., 2011) but that didn’t answer whether GM3 was the trigger, or merely the 
tombstone, of cell death. Follow-up experiments showed that GM3 plays a direct role in 
mediating neuronal cell death, as endogenous (Sohn et al., 2006) or exogenous (Nakatsuji 
and Miller, 2001) increases in GM3 levels led to neuronal death. Exogenous GM3 was 
able to induce apoptosis in all classes of neural cells, yet active proliferating cells were 
more susceptible to GM3 than post-mitotic neurons (Nakatsuji & Miller, 2001). GM3 
accumulation following glutamate-toxicity has been shown to mediate the massive 
production of ROS (Sohn et al., 2006), which leads to cell death following stroke 
(Gabryel et al., 2012). Depleting endogenous gangliosides with d-PDMP prevented the 
accumulation of GM3 and the production of ROS, and improved neuronal survival (Sohn 
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et al., 2006). Previous evidence demonstrated that augmenting ganglioside levels could 
lead to beneficial effects (Inokuchi, 1997), and it was concluded that controlling GM3 
levels should be a new therapeutic focus in managing neurodegenerative disorders (Sohn 
et al., 2006).  
1.24 GM3 in AD & Stroke  
Mounting evidence suggests the aberrant expression of gangliosides, specifically 
GM3, is involved in the pathogenesis of both stroke and AD, yet it is not clear if it is a 
point of pathological synergism as it has not been studied in a comorbid model. GM3 has 
been shown to accumulate in the infarct following MCAO (Kwak et al., 2005; Whitehead 
et al., 2011) and in cortical areas of neurodegeneration in AD brains (Kracun et al., 
1991). The first group to demonstrate GM3 accumulation in the infarct theorized it may 
be a neuroprotective response and represent an up-regulation in ganglioside biosynthesis 
(Kwak et al., 2005). More recently, the accumulation of GM3 at the border of the infarct 
was suggested to play a role in the expansion of the infarct (Whitehead et al., 2011) due 
its role in mediating glutamate toxicity (Sohn et al., 2006). It is not clear if Aβ toxicity 
will enhance the stroke-induced accumulation of GM3, or how GM3 expression will 
relate to complex ganglioside expression or neuronal survival.  
The concentrations of major gangliosides are altered in the brains of AD patients 
and transgenic mouse models (Kracun et al., 1991; Molander-Melin et al., 2005; Barrier 
et al., 2007). Specifically, GM3 has shown to accumulate in cortical areas of AD brains 
associated with neurodegeneration, while complex ganglioside levels were all decreased 
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(Kracun et al., 1991). Kracun et al. (1991) hypothesized that GM3 accumulation in AD 
brains may be the result of accelerated lysosomal degradation of complex gangliosides.  
This hypothesis was tested in an ex vivo model of AD, which has also been used 
to examine biochemical alterations in APP metabolism, anti-oxidant defense and various 
enzymatic activities in AD (Pitto et al., 2005). β-galactosidase, the lysosomal glycosidase 
responsible for the hydrolysis of GM1 to GM2, and GM2 to GM3 (Van Echten and 
Sandhoff, 1993), was assayed in fibroblasts from AD patients against age-matched 
controls by incubating cultured fibroblasts with radiolabelled exogenous GM1 (Pitto et 
al., 2005). Fibroblasts from AD patients not only showed enhanced formation of GM2 
and GM3 compared to age-matched controls (Emiliani et al., 2003), but the extent of 
GM1 hydrolysis correlated with the severity of dementia (Pitto et al., 2005). One possible 
mechanism is GM3 accumulation appears to facilitate CAA in APP transgenic mice, as 
high levels of GM3 in vascular and parenchymal tissues was associated with increased 
levels of deposited Aβ in vascular tissues (Oikawa et al., 2009; Yu et al., 2012). CAA can 
lead to microvessel damage resembling atherosclerotic lesions (Greenberg et al., 2004), 
and GM3 expression is elevated in atherosclerotic lesions (Gracheva et al. 2009; 
Bobryshev et al., 1997), which also increases the risk of microbleeds or ischemic 
hemorrhage. Therefore GM3 levels, indicative of metabolic syndrome and cardiovascular 
risk factors such as LDL cholesterol and diabetes mellitus (Inokuchi, 2011), may also 
represent a unique serum biomarker for AD risk.  
Aβ can also directly affect GM3 expression, as an in vitro study found that 
incubating hippocampal slices with pre-aggregated Aβ25-35 led to a concomitant increase 
in GM3 expression and propidium iodide uptake, indicative of peptide-induced cellular 
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death (Kreutz et al., 2011). Interestingly, soluble Aβ25-35 led to an increase in GM1 and 
GD1b expression and failed to induce cell death (Kreutz et al., 2011), indicating a pro-
survival response in ganglioside expression. Soluble Aβ, but not inverted or aggregated 
Aβ, is able to bind GM3 and inhibit the conversion of GM3 to GD3 by GD3 synthase 
(Grimm et al., 2012), which is necessary for generating the b-series gangliosides and 
some of the major brain ganglioside species such as GD1b and GT1b (Lahiri and 
Futerman, 2007) which may be another explanation for the accumulation of GM3 in AD 
brains.  
1.25 Chloroquine 
Chloroquine (CQ), 7-chloro-4-(-4-dietylamino-1-methylamino) quinolone, is 
established as a widely used anti-malarial drug and is also used as an anti-rheumatic 
agent due to its anti-inflammatory properties (Zhang et al., 2002). CQ freely diffuses 
across lipid bilayers as it is uncharged at neutral pH, but is a weak base and becomes 
protonated upon entering acidic compartments such as lysosomes (Fig. 2), causing it to 
accumulate in acidic organelles and raise their pH above their acidic optimum (Poole and 
Ohkuma, 1981; Abraham and Hendy, 1970; Zhang, 2002). This disrupts the normal 
function of acidic lysosomal enzymes such as β-galactosidase (Seglen and Gordon, 
1980), and has been used to inhibit the catabolism of gangliosides in vitro and other 
lysosome-dependent processes such as autophagy (Riboni et al., 1991,1995; Shacka et al., 
2006). CQ is able to cross the blood-brain-barrier (BBB) (Onyegbule et al., 2010), has a 
long serum half-life of approximately 5 days in man (Tracy and Webster, 1996) and has 
been shown to prevent BBB dysfunction (Mielke et al., 1997) as well as attenuate 
glutamate-induced oxidative stress in hippocampal cells (Hirata et al., 2011). 
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Figure 2 - Chemical structure of Chloroquine. Chloroquine (CQ), 7-chloro-4-(-4 
diethylamino-1-methylamino) quinolone, is uncharged at neutral pH, allowing it to 
diffuse freely across lipid bilayers into organelles such as the lysosome. In acidic 
environments, CQ gets protonated and is unable to diffuse through lipid bilayers, causing 
it to accumulate and effectively raise the pH of acidic organelles such as the lysosome. 
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As previously indicated, ganglioside catabolism is an endocytosis and lysosome-
dependent process as gangliosides are first internalized into endosomes then sent to the 
lysosomes, and in vitro if cells are treated with CQ then the formation of all degradation 
products downstream of GM1 (i.e. GM2, GM3) is prevented (Riboni et al., 1991, 1995). 
β-galactosidase is responsible for the hydrolysis of GM1 and while it cannot be targeted 
directly by pharmacological inhibition, CQ disrupts β-galactosidase activity and has 
shown to lead to the accumulation of GM1 in early endosomes and on the surface of cells 
(Yuyama et al., 2006). Other groups have used CQ in an attempt to increase GM1 
expression, which can promote acute neuroprotection and long-term functional repair 
(Hirata et al., 2011). Other autophagy inhibitors have been effective at reducing infarct 
volume and secondary neuronal death (Kubota et al., 2010; Gabryel et al., 2012; Puyal et 
al., 2009) yet their effects on the pathological accumulation of GM3 and expression of 
complex gangliosides - which are important for the maintenance and repair of CNS tissue 
- are not clear. Evidence that complex ganglioside levels are reduced following stroke 
(Ramirez et al., 2003) and that GM3 accumulates following stroke (Kwak et al., 2005; 
Whitehead et al., 2011) suggests that GM3 accumulation is the result of the accelerated 
degradation of complex gangliosides. Therefore CQ may be effective at inhibiting the 
accumulation of GM3 and maintaining expression of complex gangliosides, making it an 
ideal therapeutic candidate for the treatment of stroke.  
1.26 Rationale 
Stroke is a major risk factor for developing AD as the two pathologies share 
common risk factors and demonstrate a high co-morbidity (Iadecola, 2010; Kalaria, 
2009). When small striatal infarcts occur in the presence of Aβ they enhance the severity 
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of cognitive impairment (Snowdon et al., 1997; Heyman et al., 1998), and conversely Aβ 
enhances stroke pathology and neuronal loss through potentiation of the 
neuroinflammatory response (Koistinaho et al., 2001; Whitehead et al., 2005a,b, 2007). 
To be consistent with the epidemiological findings our lab developed a model of 
unilateral striatal infarct achieved via targeted injection of the potent vasoconstrictor 
Endothelin-1 (ET-1) which produceds transient local ischemia and a focal infarct 
(Whitehead et al., 2005a, b, 2007; Jiwa et al., 2010; Lecrux et al., 2008) with reperfusion 
occurring approximately one hour after ET-1-induced ischemia (Gelb et al., 2002). To 
compare the effects of Aβ on striatal stroke we developed a non-transgenic model of 
generalized Aβ toxicity achieved via bilateral intracerebroventricular injections of the 
neurotoxic Aβ25-35 peptide (Whitehead et al., 2005a,b, 2007). 
Inflammation represents a mechanistic point of overlap between the two 
pathologies and is regarded as the primary mechanism behind their synergistic interaction 
and neurodegeneration (Koistinaho and Koistinaho, 2005; Li et al., 2011). OX-6 staining 
will serve as a correlate of neuroinflammation by identifying ramified microglia (Vinet et 
al., 2012) while the mature neuronal marker NeuN will be used to assess neuronal loss 
along with FluoroJade B, a non-specific marker of cellular degeneration (Schmued and 
Hopkins, 2000; Damjanac et al., 2006). Anti-inflammatories are unable to ameliorate the 
effects when the two pathologies are combined (Whitehead et al., 2005b, 2010), so the 
search to identify mechanisms underlying the interaction is paramount to guide 
therapeutic strategies and identify new targets.  
Gangliosides are glycosphingolipids expressed by all vertebrate cells that are 
abundant in the CNS (Svennerholm, 1980), where they are involved in cell death and cell 
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survival processes and may determine the neuronal response to injury (Nakatsuji and 
Miller, 2001; Bektas and Spiegel, 2004). The aberrant expression of GM3 is associated 
with both stroke and AD, as GM3 accumulates in the infarct following stroke (Kwak et 
al., 2005; Whitehead et al., 2011) as well as in cortical regions in AD brains marked by 
neurodegeneration (Kracun et al., 1991). Evidence indicates that GM3 accumulation is 
the result of accelerated lysosomal degradation of complex gangliosides (Ramirez et al., 
2003; Pitto et al., 2004), and not a result of increased biosynthesis. The accumulation of 
GM3 causes neuronal death both in vitro and in vivo (Ju et al., 2005; Sohn et al., 2006; 
Nakatsuji and Miller, 2001), and has shown to mediate the production of ROS following 
glutamate toxicity (Kreutz et al., 2011), which is the primary mechanism mediating the 
propagation of stroke damage (Simon et al., 1984; Lai et al., 2011). It is unclear 
1)whether Aβ toxicity can enhance the expression of GM3 following stroke, 2) how 
complex ganglioside expression is affected and 3) whether GM3 is a potential therapeutic 
target. Thus GM3 expression will be assessed along with the complex gangliosides GM1 
and GD1b via immunohistochemistry.  
Chloroquine, a well-established anti-malarial drug and lysomotropic agent 
(Riboni et al., 1995), represents a novel therapeutic for the treatment of stroke as it has 
anti-inflammatory effects and has shown to reduce glutamate-induced toxicity in vitro 
(Hirata et al., 2011). Chloroquine impairs lysosomal activity by raising their pH above 
the acidic optimum of many lysosomal enzymes, and has been used to inhibit the 
degradation of complex gangliosides and generation of GM3 in vitro (Riboni et al., 
1991,1995) however it has never been demonstrated whether it can prevent the 
accumulation of GM3 following stroke in vivo. Therefore Chloroquine may improve 
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neuronal survival in a comorbid model by inhibiting the degradation of complex 
gangliosides, thus preventing the accumulation of GM3, and by reducing inflammation.  
1.27 Hypothesis 
Aβ toxicity will enhance the stroke-induced pathological accumulation of GM3, 
reducing expression of complex gangliosides and in turn enhancing neuronal loss; and 
Chloroquine will reduce neuronal loss by preventing the accumulation of GM3 and 
reducing inflammation. 
The following experiments will focus on three aims: 
1) Confirm GM3 expression in our ET-1 induced striatal stroke model, and 
characterize the resulting pathology and expression of complex gangliosides GM1 
and GD1b in the infarct. 
2) Characterize GM3 expression patterns at 3 and 21 days after inducing stroke, as 
well as the cellular expression profile of GM3 by immunofluorescence. 
3) Determine if CQ can prevent the accumulation of GM3 and reduce neuronal loss 
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2.1 Animals  
All experimental procedures were in accordance with guidelines of the Canadian 
Council on Animal Care and approved by Western University Animal Use Subcommittee 
(see attached certificate, Appendix). Adult male Wister rats weighing 300-400g (Charles 
River Laboratories, Quebec, Canada) were housed in pairs under standard conditions 
(12:12 LD cycle) and provided food and water ad libitum. Subjects were randomly 
assigned to their treatment groups and were housed individually following surgery. 
2.2 Surgery 
Rats were weighed before being anaesthetized in a Harvard anesthesia box with 
3% Isoflurane in 2 L/min oxygen and placed in a Kopf stereotaxic apparatus. Using an 
operating microscope, the Bregma was exposed to map and mark injection sites. 
Injections were administered with a Hamilton glass syringe at a rate of 1 µL/30 seconds 
(details below). The syringe was left in place for 3 minutes after each injection and then 
slowly removed. Body temperature was maintained at 37°C on a heating pad during the 
surgical and recovery periods before being returned to a cage.  
Animals were assigned randomly to the following treatment groups with 
coordinates relative to Bregma (Paxinos & Watson, 1986) (see Table 1 for n values): 
Amyloid toxicity (Aβ): Animals received 15 µL bilateral i.c.v injections of the toxic Aβ 
fragment, Aβ25-35 (5mmol) at coordinates -0.8 mm (anterior/posterior), ±1.4 mm 
(medial/lateral) and -4.0 mm (dorsal/ventral). Aβ25-35 (Sigma-Aldrich Co., St. Louis, 
USA) was dissolved in sterile water and stored at -80°C in 30 µL aliquots and kept on dry 
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ice right up until injection to prevent aggregation and allow better diffusion throughout 
the ventricles (Whitehead et al., 2005a, b, 2007).  
Stroke (ET-1): Animals received a 3 µL unilateral injection of the potent vasoconstrictor 
endothelin-1 (60 pmol) into the right striatum, at coordinates 0.5 mm (anterior/posterior), 
-3.0 mm (medial/lateral) and -5.0 mm (dorsal/ventral). Endothelin-1 (Sigma-Aldrich Co., 
St. Louis, USA) was in dissolved in sterile water and stored at -80°C in 3 µL aliquots and 
kept on dry ice right up until injection. Targeted injections of Endothelin-1 produces 
transient local ischemia and a focal infarct in rats (Whitehead et al., 2005a, b, 2007; Jiwa 
et al., 2010; Lecrux et al., 2008). 
Combined treatment (Aβ/ET-1): Animals received bilateral i.c.v. injections of Aβ25-35 
followed by a unilateral Endothelin-1 injection into the striatum at the same 
concentrations and coordinates as above.  
Reverse peptide (Reverse): Animals received 15 µL bilateral i.c.v. injections of the 
reverse β-amyloid fragment Aβ35-25 (5mmol), at coordinates -0.8 mm (anterior/posterior), 
±1.4 mm (medial/lateral) and -4.0 mm (dorsal/ventral). Aβ35-25 (Sigma-Aldrich, St. Louis, 
USA) was stored at -80°C in 30 µL aliquots and kept on dry ice up until injection.  
2.3 Chloroquine Administration 
Chloroquine (Sigma-Aldrich, St. Louis, USA) was prepared daily at a 
concentration of 50 mg/mL in 0.9% saline. Animals were weighed immediately prior to 
injection and were administered 45 mg/kg of CQ by intraperitoneal (i.p.) injection for 
seven consecutive days beginning three days before the surgery (Fig. 3). Dosages above 
60 mg/kg in rats were associated with toxic accidents (Del Pino et al.), and at 75 mg/kg  







Figure 3 - Chloroquine administration schedule. Chloroquing treatment began 3 days 
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acute toxicity related to the cardiovascular system (labored breathing, bradycardia, 
hypotension) were shown to increase in severity if the dosage was repeated 24 hours later 
(Zhang, 2002). A dosage of 45 mg/kg was shown to be well-tolerated in rats who 
received treatment for 6 consecutive days, and also appeared neuroprotective at this dose 
by 
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Table 1 - Treatment groups and corresponding n values. Listed are the number of animals 
that underwent successful surgeries and were included in the experiment.  












CQ ET-1 (5) 
CQ Aβ/ET-1 (5) 
CQ ET-1 (4) 
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2.5 Immunohistochemistry 
Series from each treatment group were processed simultaneously to reduce 
variability between groups. Sections were washed in 0.1 M PBS (5 x 10 minutes each), 
then quenched for 15 minutes in 1.5% hydrogen peroxide. Sections were washed in PBS 
(3 x 5 minutes each), then blocked in 1.5% bovine serum albumin (BSA) (Serological 
Research Institute, Richmond, USA) diluted in PBS with Triton-X (PBST) for 30 
minutes. Sections were incubated with primary antibodies diluted in 1.5% BSA (PBST) 
for 48 hours at 4°C on a shaker. Immunohistochemistry procedure was similar for: mouse 
anti-rat OX-6 (1:1000, BD Biosciences, Mississauga, Canada), NeuN (1:1000, EMD 
Millipore, Billerica, USA), GFAP (1:1000, EMD Millipore, Billerica, USA) GM3 (1:500, 
Seikagaku Corporation, Tokyo, Japan), GM1 and GD1b (1:500, Ronald Schnaar, Johns 
Hopkins University, USA); however Triton-X was not used for GM3, GM1 or GD1b 
staining due to its membrane delocalizing effects (Lopez & Schnaar, 2009). 
Sections were washed in PBS (5 x 5 minutes each) then incubated with HRP-
conjugated secondary antibodies diluted in 1.5% BSA (PBST) for 1 hour. HRP-
conjugated (anti-mouse IgG) (1:200, Vector Laboratories, Burlington, Canada) and anti-
rabbit IgG secondary antibodies (1:200, Vector Laboratories, Burlington, Canada) were 
used for the appropriate primary antibodies. Sections were washed in PBS (3 x 5 minutes 
each) then incubated in Avidin-Biotinylated Complex (ABC) reagent (Vector 
Laboratories, Burlington, Canada) for 1 hour. Sections were washed in PBS (3 x 5 
minutes each) then developed in fresh 0.001% Diaminobenzidine (DAB) (Vector 
Laboratories, Burlington, Canada) at 10 mg in 20 mL PBS with 300 µL 3% H202, Sigma 
	   	   	   	   	  
	  48	  
for 5 minutes. Sections were washed in PBS (3 x 10 minutes each) then mounted onto 
VWR microscope slides in 0.3% gelatin 
2.6 Immunohistochemical Controls 
Secondary controls using anti-mouse and anti-rabbit HRP-conjugated secondary 
antibodies were performed as negative controls, and a typical section showed no non-
specific binding (Fig. 12a). Further, in order to confirm the detection of GM3 antibody, a 
series of control immunohistochemical procedures were carried out. These included a 
secondary control, in which the anti-GM3 antibody was left out of the primary incubation 
(1.5% BSA only); a competitive co-incubation, in which 0.5 mg of excess GM3 
ganglioside (Seikagaku Corporation, Tokyo, Japan) was co-incubated for the 48 hour 
primary incubation with anti-GM3 primary antibody; and lastly the primary GM3 
antibody was tested on an embryonic day 13.5 mouse brain as a positive control, 
following the same immunohistochemical procedures once the fresh-frozen tissue was 
thaw-mounted onto a microscope slide and post-fixed in PFA for 10 minutes.  
2.7 Fluoro Jade B protocol 
Sections were washed in PBS (6 x 10 minutes each) then mounted onto 
microscope slides with 0.3% gelatin and allowed to dry overnight. Slides were placed in 
1% sodium hydroxide in 80% ethanol for 5 minutes. Slides were then rehydrated in 95% 
ethanol for 3 minutes; 70% ethanol for 3 minutes; 50% ethanol for 2 minutes, and finally 
distilled water (3 x 1 minute each). Slides were then incubated in 0.06% potassium 
permanganate (KMnO4) for 15 minutes on a shaker, in the dark. Slides were then washed 
in distilled water (3 x 1 minute each), then placed in fresh 0.0004% Fluoro Jade B 
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(Millipore, Billerica, USA) in 0.1% acetic acid for 20 minutes on a shaker in the dark. 
Afterwards slides were washed in distilled water (3 x 1 minute each) then allowed to dry 
in the fume hood before a xylene wash (1 minute) and coverslip with Depex.   
2.8 Immunofluorescence  
Free-floating sections were washed in PBS (3 x 10 minutes) then blocked in 1.5% 
BSA for 1 hour at room temperature. Sections were incubated with GM3 [1:500] and 
either NeuN (1:1000, Millipore, Billerica, USA), GFAP (1:1000, Millipore, Billerica, 
USA) or IBA-1 for activated microglia/macrophages (1:1000, Santa Cruz Biotechnology 
Inc., Santa Cruz, USA) in 1.5% BSA for 48 hours at 4° C.  
Sections were washed in PBS (3 x 10 minutes each) then incubated with FITC-
conjugated anti-mouse IgG (1:300, Santa Cruz Biotechnology Inc., Santa Cruz, USA) and 
TR-conjugated anti-rabbit IgG (1:300, Santa Cruz Biotechnology Inc., Santa Cruz, USA) 
for 1 hour at room temperature in the dark. Sections were washed in PBS (3 x 10 
minutes) and mounted onto microscope glass slides in 0.3% gelatin and allowed to dry 
overnight before a xylene wash (1 minute) and coverslipped with Depex.  
2.9 Imaging  
Images were taken on a Leica DC300 (Leica Microsystems, Concord, Canada) 
camera microscope. Analysis and quantification was carried out using ImageJ (Wayne 
Rasband, National Institute of Health, Bethesda, USA) by one observer who was blinded 
to the treatment group.  
The following parameters were used for analysis: 
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Expression volume 
Expression volume of OX-6 (“Inflammation Volume”) and GM3 (“GM3 
Expression Volume”) in the striatum ipsilateral to the stroke were calculated as correlates 
of infarct volume.  
The striatum was defined based on the following bordering landmarks: superiorly 
and laterally by the corpus callosum, medially by the lateral ventricle, and inferiorly by 
the anterior commissure. An entire series (approximately 24 sections) was stained from 
each brain for OX-6 and GM3 respectively, from -1.2 mm to 3.8 mm relative to Bregma. 
After sections had been mounted and cover-slipped they were scanned (Epson Scanner) 
and analyzed in ImageJ (NIH, Maryland, USA). Images were inverted to improve 
contrast, with a threshold for a positive stain set at a mean intensity of 75 out of 255. 
Expression volume was normalized to the ipsilateral (ischemic) and contralateral (non-
ischemic) hemispheres to account for any contribution of hemispheric swelling (Lin et 
al., 1993), and was calculated using the equation: 
Volume = (Σ(Infarct Surface Area x (Contralateral/Ipsilateral Hemisphere))) x Length 
Length was defined as the number of sections on which the infarct was measured minus 1 
(n-1), multiplied by the thickness of the sections (35 µm) and the distance between 
sections (280 µm).  
Optical Density 
Optical density measurements of OX-6 and GM3 staining were taken as correlates 
of the number of microglia and concentration of GM3. Arbitrary units were assigned to 
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compare optical density. Different treatment groups were always processed 
simultaneously with the same solutions in order to reduce variation in DAB staining. 
Density values of OX-6 and GM3 staining were normalized as follows: the mean 
intensity values of the measurements used for infarct volume were averaged for each 
brain and normalized with the values from the appropriate comparison group, with the 
highest value assigned 100 and the lowest value assigned 0. Comparisons of optical 
density show the average value per group, and were only carried for groups processed 
simultaneously.   
Neuronal Quantification (%NeuN Expression) 
Expression of the neuron-specific protein NeuN in the ipsilateral striatum was 
quantified as the average ratio of ipsilateral/contralateral striatal NeuN positive cells from 
three sections per brain. The average for each brain was taken from three slices at the 
approximate Bregma levels 0.6 to 0.8 mm; 0 to -1.2; and -1.4 to -1.8 mm 
anterior/posterior. Images were taken at a 1.5x magnification, and NeuN positive cells 
were counted using the Analyze Particles tool in ImageJ. This approach proved effective 
as differences in Bregma level affect striatal area, however the values were normalized to 
an internal control (contralateral striatum).  
Fluoro Jade B Cell Counts 
Fluoro Jade B (FJB), a marker for cellular degeneration (Schmued and Hopkins, 
2000; Damjanac et al., 2006) cell counts were counted manually as the average number 
of FJB-positive cells in the ipsilateral striatum from three brain slices. No FJB positive 
cells were detected in the contralateral striatum. The average for each brain was taken 
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from three slices at the approximate Bregma levels 0.6 - 0.8 mm; 0 – (-1.2); and (-1.4) – 
(-1.8) mm anterior/posterior, counted under 16x magnification.  
Quantification of Complex Gangliosde Expression (%GM1/GD1b Expression) 
The mean intensity value from a 0.33 mm2 area was measured from the infarct in the 
ipsilateral striatum and compared against the corresponding area in the contralateral 
striatum as the ratio of ipsilateral/contralateral staining intensity, expressed as the percent 
difference (reduction) from the expected difference of 0. Values are the average of three 
measurements per brain.  
2.10 Determination of Aβ Aggregation State 
To confirm that Aβ was not aggregated upon injection, Aβ25-35 underwent matrix-
assisted laser desorption/ionization (MALDI) mass spectrometric analysis to determine 
aggregation state of the Aβ peptide under similar conditions to surgery. Aβ25-35 is 
typically aggregated at room temperature for several days (Kreutz et al., 2011). Aβ25-35 (5 
mmol) was kept on dry ice right up until it was spotted onto a 41 mm x 41 mm stainless 
steel MALDI plate (AB Sciex, Foster City, USA), The plate was dried in a vaccuum for 
20 minutes then placed in a humidor at ambient temperature at 80% relative humidity for 
40 minutes. The plate was then sprayed manually with α-cyano-4-hydroxycinnamic acid 
(CHCA) matrix using an airbrush. MS/MS analysis was done on an Applied Biosystems 
4800 MALDI TOF/TOF.  
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2.11 Data Analysis 
Statistical analysis was performed using Prism 4.0 (GraphPad) for Windows. 
Two-tailed Student’s t-tests were used for two-group comparisons, while comparisons of 
multiple groups were carried out using a randomized one-way analysis of variance 
(ANOVA). Significance between groups was determined by Tukey’s post-test. Linear 
regression analysis was performed using Excel (Microsoft Corporation) un-blinded, as 
animal ID’s were used to pair appropriate measures. Numerical data are presented as 
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3.1 Effects of Aβ Toxicity and Stroke 
3.1.1 Aggregation State of Aβ25-35 
Soluble Aβ25-35 has demonstrated neurotoxicity both in vitro and in vivo as well as 
the ability to aggregate (Yankner et al., 1990; Pike et al., 1995; Tsuruma et al., 2010; 
Kowall et al., 1992), and compared to the full-length Aβ peptides allows for greater 
diffusion throughout the ventricles to induce generalized Aβ toxicity in our model 
(Whitehead et al., 2005a; 2007a; Cheng et al., 2006). There are conflicting results relating 
the aggregation state of Aβ to its neurotoxicity (Kruetz et al., 2011; Tam and Pasternak, 
2012; Benilova et al., 2012), however, soluble Aβ species, and not amyloid plaques, have 
shown to correlate with synaptic loss (Benilova et al., 2012; Tam and Pasternak, 2012), 
further supporting the use of soluble Aβ to model the neurodegenerative mechanisms in 
the brain at risk for developing AD.  
Preparation of the Aβ25-35 sample for MALDI analysis took approximately an 
hour, during which time the spotted Aβ25-35 was at room temperature. Thus it was 
exposed to room temperature for significantly longer than it would be during surgical 
procedure and injection (approximately 25 minutes). Aβ25-35 gave a strong signal at 
1082.78 m/z (mass-to-charge ratio, equivalent mass units) (Fig. 4), which is the Na+ 
adduct of Aβ25-35: in order for detection to occur, analytes must be desorbed from the 
sample and ionized in order to traverse the vacuum, which is mediated by the matrix. To 
illustrate this point, there is no peak corresponding to the molecular mass of the Aβ25-35 
molecule (1062 m/z). There were no Aβ aggregates or oligomers detected, as MALDI 
allows for the detection of higher mass proteins and protein aggregates (Caprioli et al.,  




Figure 4 - MALDI analysis of Aβ aggregation state. Aβ25-35 underwent MALDI mass 
spectral analysis on an Applied Biosystems 4800 MALDI TOF/TOF with CHCA matrix. 
The strong signal peak at 1082.78 m/z represents the Na+ adduct of Aβ25-35. There were 
no masses detected above 1500 m/z units, indicating there were no Aβ aggregates or 
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1997), suggesting there is little to no aggregation of Aβ25-35 upon exposure to room 
temperature for 60 minutes.  
3.1.2 Aβ & Reverse Animals Lack Striatal Pathology  
Aβ and Reverse animals demonstrated no OX-6 expression (Fig. 5a,e), cellular 
degeneration (Fig. 5b,f) neuronal loss (Fig. 5c,g) or GM3 accumulation (Fig. 5d,h) in the 
striatum at 21 days after bilateral i.c.v. injections. Since the stroke-induced pathology is 
restricted to the striatum, Aβ and Reverse groups are excluded from all subsequent 
figures and analyses.  
3.1.3 OX-6 Expression: Neuroinflammatory Response 
The activation, proliferation and migration of microglia is a critical component of 
both the acute and chronic neuroinflammatory response (Stoll et al., 1998). Series were 
stained with the microglial marker OX-6 to examine microglial reactivity (Vinet et al., 
2012) and serve as a correlate of neuroinflammation. At 3 days after surgery, ET-1 and 
Aβ/ET-1 animals were not significantly different based on the number of microglial cells 
identified by OX-6 expression volume – normalized for hemispheric swelling - or OX-6 
staining intensity – normalized between groups - in the ipsilateral striatum (p > 0.05, n = 
6 each, Fig. 6e,j). Microglia were present throughout the infarct region at a similar 
concentration and exhibited a rounded morphology (Fig. 6g,i).  
At 21 days after surgery, OX-6 immunostaining revealed the inflammatory 
response was still active at 21 days, as both ET-1 and Aβ/ET-1 rats showed a significant 
increase in OX-6 expression volume from 3 days (225% and 709%, respectively, p < 
0.05, Fig. 7e). Both groups displayed highly ramified microglia that were densely  
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Figure 5 - Striatal pathology is absent in Aβ and Reverse animals at 21 days after surgery. 
Photomicrographs of brain sections from an Aβ (n = 6) and Reverse (n = 4) rat 
corresponding to the area of the infarct demonstrate no observable striatal pathology, 
assessed by (a,e) OX-6 expression for ramified microglia; (b,f) Fluoro Jade B detection 
for cellular degeneration; (c,g) neuronal protein marker NeuN expression for neuronal 
loss, and (d,h) pathological expression of GM3. Sections are taken from the same animal 
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Figure 6 - Aβ toxicity had no effect on OX-6 expression at 3 days after surgery. (a-d) 
Photomicrographs of ramified microglia, identified by OX-6 staining in the striatum of 
ET-1 (n = 6) and Aβ/ET-1 (n = 4) animals at 3 days after surgery. Areas boxed in lower 
power (1.5x) photomicrographs (a-d) are shown in higher power (10x) in panels (f-i) and 
demonstrate similar microglial morphology at 3 days between groups, with expression 
limited to the ipsilateral striatum. (e) OX-6 expression volume and (j) OX-6 staining 
intensity quantified throughout the ipsilateral striatum at 3 days (T-test: Volume, t8= 
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Figure 7 – OX-6 expression at 21 days after surgery. Photomicrographs of ramified 
microglia immunostained by OX-6 in the striatum of ET-1 (n = 6) and Aβ/ET-1 (n = 6) 
animals at 21 days after surgery. Areas boxed in lower power (1.5x) photomicrographs 
(a-d) are shown in higher power (10x) in panels (f-i) and demonstrate highly ramified 
microglia concentrated in the infarct core in the ipsilateral striatum. (e) OX-6 expression 
volume and (j) OX-6 staining intensity quantified throughout the ipsilateral striatum at 21 
days (T-test: Volume, t10 = 1.458, p = 0.18; Optical Density, T-test: t10 = 1.517, p = 0.16). 
Percentages and * indicate % change and significance from 3 day animals (T-test: ET-1, 
t10 = 2.513, p < 0.05; Aβ/ET-1, t8 = 1.817, p < 0.05). *p < 0.05. 
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concentrated in the infarct (Fig. 7g,i). There was no significant difference in OX-6 
expression volume or staining intensity between groups at 21 days after surgery (p > 
0.05, Fig. 7e,j), though Aβ/ET-1 rats showed approximately a two-fold increase in OX-6 
expression volume compared to ET-1 rats. 
3.1.4 Fluoro Jade B: Cellular Degeneration 
Fluoro Jade B (FJB) is a polyanionic molecule that binds polyamines, which are 
compounds that accumulate in degenerating cells regardless of cause or type of cell death 
(Schmued and Hopkins, 2000; Damjanac et al., 2006). Therefore FJB is ideal for 
assessing stroke-induced cell death, which includes both necrotic and apoptotic pathways 
(Gabryel et al., 2012).  
At 3 days, ET-1 and Aβ/ET-1 exhibited obvious cellular degeneration as FJB-
positive cells were extensively – and exclusively - distributed throughout the infarct core 
(Fig. 8a,b). Quantifying FJB expression showed there was no significant difference in the 
total number of FJB positive cells at 3 days after surgery (p > 0.05, Fig. 8c), indicating 
there was no acute effect of Aβ on stroke-induced cell death.  
At 21 days after surgery, both ET-1 and Aβ/ET-1 rats showed a significant 
reduction in the number of FJB positive cells in the ipsilateral striatum (p < 0.001, p < 
0.05, respectively) as they were largely absent in the necrotic core and concentrated along 
the periphery of the infarct (Fig. 8d,e). Aβ/ET-1 rats had 33% more FJB positive cells at 
21 days compared to ET-1 rats, and while there was no significant difference in FJB cell 
counts between ET-1 and Aβ/ET-1 rats at 21 days after surgery (p > 0.05, Fig. 8f), 
Aβ/ET-1 rats showed a much smaller – though still significant - decrease from 3 days. 
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Figure 8 – Cellular degeneration at 3 and 21 days after surgery in the infarct assessed by 
Fluoro Jade B. (a,b) Photomicrographs (16x) of degenerating cells in the ipsilateral 
striatum identified by Fluoro Jade B (FJB) at 3 and 21 (d,e) days after surgery in ET-1 
and Aβ/ET-1 animals. FJB positive cells indicate extensive cellular degeneration in the 
infarct core at 3 days after surgery, and at the border of the infarct at 21 days after 
surgery. (c) Counts of FJB positive cells at 3 and (f) 21 days after surgery in ET-1 and 
Aβ/ET-1 animals (n = 6, n = 6, n = 4, n = 6 respectively). There were no significant 
differences between groups at 3 or 21 days in cell counts (T-test: 3 day, t8 = 1.176, p = 
0.27; 21 day, t10 = 1.735, p = 0.11). Percentages are 21 day values as a percentage of 3 
day values, and * indicate significance from 3 day animals (T-test: ET-1, t10 = 5.772, p < 
0.001; Aβ/ET-1, t8 = 2.309, p < 0.05). Values are averaged from 3 sections per brain. *p 
< 0.05, ***p < 0.001. 
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These data suggest that in the absence of Aβ toxicity, endogenous repair mechanisms are 
more effective at preventing progressive cellular loss following ischemic stroke.  
3.1.5 NeuN - Neuronal Survival 
To complement the FJB data indicating robust cellular degeneration, sections 
were stained with the neuronal marker NeuN to provide an estimate of neuronal loss in 
the ipsilateral striatum. The number of neurons immunoreactive for NeuN in the 
ipsilateral striatum was expressed as a ratio of those in the contralateral striatum, 
providing an internal control that allowed for more accurate comparisons.  
At 3 days after surgery, there was no significant difference in NeuN expression 
between ET-1 and Aβ/ET-1 animals (p > 0.05, Fig. 9e), however both groups showed 
substantial neuronal loss in the ipsilateral striatum, losing roughly 35% and 40% of NeuN 
positive neurons, respectively (Fig. 9b,d). The infarct core wasn’t clearly defined yet at 3 
days, however, as NeuN-positive cells were still present throughout the core of the infarct 
(Fig. 9g,i).  
From 3 to 21 days after surgery, both ET-1 and Aβ/ET-1 rats showed non-
significant progressive neuronal loss, losing an additional 7.2% and 15.6% of NeuN 
positive neurons, respectively (p > 0.05). Aβ/ET-1 rats showed significantly greater 
neuronal loss at 21 days compared to ET-1 rats, with only 45% of NeuN positive neurons 
remaining compared to 58% in ET-1 rats (p < 0.05, Fig. 10e). Necrosis of the core is 
likely to have contributed to the progressive neuronal loss, as NeuN positive cells are 
almost completely absent from the core of the infarct at 21 days after surgery (Fig. 10g,i), 
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Figure 9 – Expression of neuronal protein NeuN at 3 days after surgery. (a-d) 
Photomicrographs of neurons identified by NeuN in the striatum of ET-1 and Aβ/ET-1 
animals at 3 days after surgery. Areas boxed in lower power (1.5x) photomicrographs (a-
d) are shown in higher power (16x) in panels (f-i), demonstrating decreased NeuN 
expression in the infarct. (e) Counts of neurons in the ipsilateral striatum identified by 
NeuN in ET-1 (n = 6) and Aβ/ET-1 (n = 4) animals, expressed as a ratio of NeuN 
expression in the contralateral striatum (T-test: t8 = 0.48, p = .64). Values are averaged 
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Figure 10 – Aβ/ET-1 showed progressive neuronal loss at 21 days after surgery. (a-d) 
Photomicrographs of neurons identified by NeuN in the striatum of ET-1 and Aβ/ET-1 
animals at 21 days after surgery. Areas boxed in lower power (1.5x) photomicrographs 
(a-d) are shown in higher power (16x) in panels (f-i), demonstrating absence of NeuN 
expression in the infarct. (e) Counts of neurons in the ipsilateral striatum identified by 
NeuN in ET-1 (n = 6) and Aβ/ET-1 (n = 6) animals, expressed as a ratio of NeuN 
expression in the contralateral striatum (T-test: t10 = 2.838, p < 0.05). Percentages 
indicate change from corresponding 3 day animals (T-test: ET-1, t10 = 1.223, p = 0.25; 
Aβ/ET-1, t8 = 2.23, p = 0.056). Values are averaged from 3 sections per brain. *p < 0.05. 
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but expansion of the infarct into the penumbra is also evident from 3 (Fig. 9b,d) to 21 
(Fig. 10b,d) 21 days after surgery. Once again, in the absence of Aβ toxicity there appear 
to be endogenous mechanisms that promote repair or prevent progressive cell loss after 
the initial acute ischemic event, as Aβ toxicity leads to progressive cellular and neuronal 
loss.  
3.1.6 Pathological Ganglioside Expression: GM3 Accumulation 
The effect of striatal stroke - alone and in combination with Aβ toxicity - on 
pathological ganglioside expression was assessed by immunostaining with an anti-GM3 
antibody, as GM3 has been shown to accumulate following MCAO in the infarct (Kwak 
et al., 2005; Whitehead et al., 2011). GM3 was detected at 3 days in ET-1 and Aβ/ET-1 
animals, though its expression was limited to the infarct (Fig. 11b,d), as it was likely 
below detection threshold throughout the rest of the brain. GM3 positive cells were 
present throughout the infarct (Fig. 11g,i), with many exhibiting a neuronal morphology 
(Fig. 11k,l). At 3 days after surgery, there was no significant difference between ET-1 
rats and Aβ/ET-1 rats in GM3 expression volume (p > 0.05, Fig. 11e) or staining intensity 
(p > 0.05, Fig. 11j).   
At 21 days, GM3 expression volume (Fig. 12e) – normalized for hemispheric 
swelling - and staining intensity (Fig. 12j) – normalized between groups - was 
significantly greater in Aβ/ET-1 animals compared to ET-1 animals (p < 0.05). There was 
a significant reduction in GM3 expression volume in ET-1 animals from 3 to 21 days (p < 
0.05), while Aβ/ET-1 animals showed a non-significant increase in GM3 expression 
volume (p > 0.05). GM3 staining appeared primarily extracellular in the infarct core, 
	   	   	   	   	  
	  67	  
 
Figure 11 – GM3 expression in the infarct at 3 days after surgery. (a-d) Photomicrographs 
of GM3 immunostaining in the ipsilateral striatum of ET-1 and Aβ/ET-1 animals at 3 
days after surgery. Areas boxed in lower power (1.5x) photomicrographs (a-d) are shown 
in higher power (16x) in panels (f-i), and again in panels (40x) (k,l) demonstrating the 
neuronal morphology of GM3 positive cells. (e) GM3 expression volume and (j) GM3 
staining intensity quantified throughout the ipsilateral striatum at 3 days in ET-1 (n = 6) 
and Aβ/ET-1 (n = 4) animals (T-test: Volume, t8 = 1.034, p = 0.33; Optical Density, t8 = 
0.07, p = 0.95). 
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Figure 12 - Aβ toxicity enhanced stroke-induced expression of GM3 at 21 days after 
surgery. (a-d) Photomicrographs of GM3 expression of GM3 immunostaining in the 
ipsilateral striatum of ET-1 and Aβ/ET-1 animals at 21 days after surgery. Areas boxed in 
lower power (1.5x) photomicrographs (a-d) are shown in higher power (16x) in panels (f-
i), demonstrating the predominantly extracellular expression of GM3. (e) GM3 
expression volume and (j) GM3 staining intensity quantified throughout the ipsilateral 
striatum at 21 days in ET-1 (n = 6) and Aβ/ET-1 (n = 6) animals (T-test: Volume, t10 = 
2.234, p < 0.05; Optical Density, t10 = 2.987, p < 0.05). Percentages are 21 day values as 
a percentage of 3 day values, and * indicates significance from 3 day animals (T-test: ET-
1, t10 = 2.804, p < 0.05; Aβ/ET-1, t8 = 1.163, p = 0.28). *p < 0.05. 
 
	   	   	   	   	  
	  69	  
with a cellular staining pattern in the periphery of the infarct region along the border (Fig. 
12g,i). 
3.1.7 GM1 and GD1b: Expression of complex gangliosides 
Sections were immunostained for GM1 and GD1b to examine the effect of stroke 
on complex ganglioside expression in the context of GM3 accumulation, in order to 
determine if GM3 accumulation does in fact represent a protective response and 
increased ganglioside biosynthesis as proposed by Kwak et al. (2005). To quantify 
changes in the expression of GM1 and GD1b, which are ubiquitously expressed 
throughout the brain, and control for variation in DAB staining, staining intensity in the 
infarct was evaluated relative to the contralateral striatum as a way to detect differences 
in expression level by immunohistochemistry. As both GM1 and GD1b staining intensity 
was reduced in the infarct relative to the contralateral striatum, values were expressed as 
the % reduction relative to the contralateral striatum, and analyzed between groups and 
against the expected difference of 0.  
At 3 days after surgery, GM1 staining intensity was significantly reduced in the 
infarct compared to the contralateral striatum for both ET-1 and Aβ/ET-1 rats (Fig. 13b,d, 
p < 0.01) however there was no significant difference between groups (p > 0.05, Fig. 
13e). GM1 expression was diffuse throughout the striatum, and also appeared to a lesser 
extent in the corpus callosum (Fig. 13a-d). At 21 days, GM1 staining intensity was 
significantly reduced in the infarct for both ET-1 and Aβ/ET-1 groups (Fig. 13g,i, p < 
0.05), but there was no significant difference between groups (Fig. 13j, p > 0.05) and  
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Figure 13 – GM1 expression at 3 and 21 days after surgery in the infarct. (a-d) 
Photomicrographs of GM1 immunostaining in the striatum of ET-1 and Aβ/ET-1 animals 
at 3 and 21 (f-i) days after surgery (1.5x). GM1 expression is diffuse throughout the 
striatum, yet decreased in the infarct. Quantification of reduced GM1 expression in ET-1 
and Aβ/ET-1 animals at 3 (e) and 21 (j) days after surgery (n = 6, n = 4, n = 6, n = 6 
respectively) expressed as the reduction in GM1 staining intensity in the infarct relative 
to the contralateral striatum, analyzed against the expected difference of 0 (T-test: 3d ET-
1, t5 = 8.61, p < 0.01; 3d Aβ/ET-1, t3 = 7.171, p < 0.01; 21 d ET-1, t5 = 7.165, p < 0.05; 
21d Aβ/ET-1, t5 = 2.752, p < 0.05). There was no significant difference between groups 
at 3 or 21 days (T-test: 3d, t8 = 2.011, p = 0.09; 21d, t10 = 0.125, p = 0.9). Values are the 
average of 3 measurements per brain. *p < 0.05, **p < 0.01. 
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there was no significant difference from 3 days for either group (p > 0.05). GM1 
appeared highly concentrated around the infarct at 21 days (Fig. 13g,i). 
At 3 days after surgery, GD1b staining intensity in the infarct was significantly 
reduced compared to the contralateral striatum in both ET-1 and Aβ/ET-1 rats (Fig. 
14b,d, p < 0.05, p < 0.01 respectively) however there was no significant difference 
between groups (Fig. 14e, p > 0.05). GD1b staining appeared diffuse throughout the 
striatum and the corpus callosum at 3 days after surgery (Fig. 14a-d). At 21 days after 
surgery, GD1b staining intensity was significantly decreased in both ET-1 and Aβ/ET-1 
rats compared to the contralateral striatum (Fig. 14j, p < 0.05). There was no significant 
difference between groups in reduction of GD1b staining intensity (Fig. 14j, p > 0.05), 
and there was no significant difference between 3 and 21 days after surgery for ET-1 or 
Aβ/ET-1 rats (p > 0.05). GD1b expression was highly concentrated around the infarct at 
21 days after surgery, and again was diffuse throughout the striatum and present in the 
corpus callosum (Fig. 14g,i) 
3.1.8 GM3 Immunohistochemical Controls 
To confirm detection of GM3 by immunohistochemistry, several standard control 
protocols were run on sections from an Aβ/ET-1 21 day brain to assess the sensitivity and 
specificity of the anti-GM3 primary antibody. Upon omitting the anti-GM3 primary 
antibody (Fig. 15a,e) or co-incubating with excess GM3 (Fig. 15b,f), there was no 
positive stain detected in the ipsilateral striatum. Under standard IHC protocol, GM3 is  
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Figure 14 – GD1b expression at 3 and 21 days after surgery in the infarct. (a-d) 
Photomicrographs of GD1b immunostaining in the striatum of ET-1 and Aβ/ET-1 
animals at 3 and 21 (f-i) days after surgery (1.5x). GD1b expression is diffuse throughout 
the striatum, yet decreased in the infarct. Quantification of reduced GD1b expression in 
ET-1 and Aβ/ET-1 animals at 3 (e) and 21 (j) days after surgery (n = 6, n = 4, n = 6, n = 6 
respectively) expressed as the reduction in GD1b staining intensity in the infarct relative 
to the contralateral striatum, analyzed against the expected difference of 0 (T-test: 3d ET-
1, t5 = 3.591, p < 0.05; 3d Aβ/ET-1, t3 = 8.964, p < 0.01; 21d ET-1, t5 = 3.933, p < 0.05; 
21d Aβ/ET-1, t5 = 6.584, p < 0.05). There was no significant difference between groups 
at 3 or 21 days (T-test: 3d, t8 = 0.8554, p = 0.43; 21d, t10 = 1.503, p = 0.21). Values are 
the average of 3 measurements per brain. *p < 0.05, **p < 0.01. 
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Figure 15 - Immunohistochemical controls for detection of GM3. Photomicrographs of 
immunohistochemical controls in adjacent brain sections from a 21 day Aβ/ET-1 rat to 
confirm detection of GM3: (a) negative control with primary anti-GM3 antibody omitted 
from primary incubation, (b) preabsorption of primary anti-GM3 antibody with excess 
GM3, (c) standard immunostaining of GM3 in the infarct, and (d) positive control with 
primary anti-GM3 antibody tested in a day 13.5 embryonic mouse brain. Areas boxed in 
lower power (1.5x) photomicrographs (a-d) are shown in higher power (15x) in panels e-
h. 
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detected in the infarct (Fig. 15c,g). As a positive control embryonic mouse brain was 
stained with the anti-GM3 primary antibody, as GM3 is expressed in the developing CNS 
(Nakatsuji and Miller, 2001) and demonstrated a positive stain (Fig. 15d,h). 
3.1.9 Dual-labeled immunofluorescence 
Immunofluorescence was performed on adjacent sections from a 21 day Aβ/ET-1 
brain to demonstrate the cellular expression profile of GM3, and to determine whether 
GM3 expression is associated with a positive FJB signal, indicating cellular degeneration. 
GM3 co-localizes extensively with neurons in the periphery of the infarct (Fig. 16c). At 
21 days, GFAP-positive astrocytes surround the infarct at the border of the infarcted 
tissue and show no co-localization with GM3 (Fig.16f). IbA-1 positive microglia are 
present throughout the infarct, and roughly half appear to co-localize with GM3 (Fig. 
16i). Lastly, the majority of FJB positive cells within the periphery of the infarct appear 
to co-localize with GM3 (Fig. 16l).  
3.2 Effects of Chloroquine  
3.2.1 OX-6 Expression in Chloroquine Animals 
At 3 days after surgery, CQ ET-1 and CQ Aβ/ET-1 rats were not significantly 
different based on the number of microglia identified by OX-6 expression volume or OX-
6 staining intensity in the ipsilateral striatum (Fig. 17e,j, p > 0.05). Microglia were 
present throughout the infarct region at a similar density and exhibited a rounded 
morphology (Fig. 17g,i). CQ treatment had no effect on OX-6 expression volume at 3 
days, as there were no significant differences between untreated and treated groups (Fig. 
19a, p > 0.05).  
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Figure 16 – Immunofluorescent dual labeling with GM3. Photomicrographs (16x) of 
GM3 expression in the striatum from a 21d Aβ/ET-1 animal dual labeled with (a-c) 
neuronal protein NeuN in the periphery of the infarct, (d-f) astrogliosis marker GFAP at 
the border of the infarcted tissue, (g-i) macrophage/microglial protein IbA-1 in the core 
of the infarct and (i-l) Fluoro Jade B, a marker of cellular degeneration at the periphery of 
the infarct. GM3 co-localizes well with NeuN and FJB, with some co-localization with 
IbA-1.  
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Figure 17 – OX-6 expression at 3 days after surgery in Chloroquine-treated animals. (a-d) 
Photomicrographs of ramified microglia identified by OX-6 staining in the striatum of 
CQ ET-1 (n = 5) and CQ Aβ/ET-1 (n = 5) animals at 3 days after surgery. Areas boxed in 
lower power (1.5x) photomicrographs (a-d) are shown in higher power (10x) in panels (f-
i) and demonstrate similar microglial morphology between groups, with expression 
limited to the ipsilateral striatum. (e) OX-6 expression volume and (j) OX-6 staining 
intensity quantified throughout the ipsilateral striatum at 3 days (T-test: Volume, t8 = 
1.166, p = 0.28; Optical Density, t8 = 1.053, p = 0.32).  
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From 3 to 21 days after surgery, OX-6 expression volume in CQ ET-1 rats had 
decreased by almost 50%, while in CQ Aβ/ET-1 rats OX-6 expression volume had 
increased by almost 200%; compared to the 225% and 709% increases in ET-1 and 
Aβ/ET-1 rats from 3 to 21 days. While CQ effectively reduced the progressive increase in 
OX-6 expression volume, results still implicate Aβ toxicity in aggravating stroke induced 
OX-6 expression over time. CQ ET-1 and CQ Aβ/ET-1 rats were not, however, 
significantly different in OX-6 expression volume (Fig. 18e, p > 0.05) or OX-6 staining 
intensity (Fig. 18j, p > 0.05) at 21 days after surgery. Microglia appeared ramified and 
highly concentrated in the infarct region at 21 days (Fig. 18g,i). CQ treatment resulted in 
non-significant reductions in OX-6 expression volume at 21 days compared to untreated 
animals for both CQ ET-1 and CQ Aβ/ET-1 animals (29.9% and 22.1% of untreated OX-
6 expression volumes, respectively, Fig. 19b, p > 0.05).  
3.2.2 Fluoro Jade B in Cholorquine-Treated Animals 
At 3 days after surgery, FJB positive cells were present throughout the core of the 
infarct in both CQ ET-1 and CQ Aβ/ET-1 rats (Fig. 20a,b) and FJB cell counts in the 
ipsilateral striatum showed no significant difference between CQ-treated groups (Fig. 
20c, p > 0.05). CQ treatment led to non-significant reductions in the number of FJB cells 
at 3 days after surgery in CQ ET-1 and CQ Aβ/ET-1 rats compared to the corresponding 
untreated groups (76.2% and 54% of untreated FJB cell counts, respectively, Fig. 21a, p 
> 0.05). From 3 to 21 days after surgery, both CQ ET-1 and CQ Aβ/ET-1 rats showed 
non-significant reductions in FJB cell counts (32.2% and 61.1% of 3 day counts, 
respectively, p > 0.05). At 21 days, FJB cells were concentrated mostly in the perimeter 
of the infarct, with few FJB-positive cells present in the core of the infarct (Fig. 20d,e).  
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Figure 18 – OX-6 Expression at 21 days after surgery in Chloroquine-treated animals. (a-
d) Photomicrographs of ramified microglia, identified by OX-6 staining in the striatum of 
CQ ET-1 (n = 4) and CQ Aβ/ET-1 (n = 5) animals at 21 days after surgery. Areas boxed 
in lower power (1.5x) photomicrographs (a-d) are shown in higher power (10x) in panels 
(f-i) and demonstrate highly ramified microglia concentrated in the infarct core in the 
ipsilateral striatum. (e) OX-6 expression volume and (j) OX-6 staining intensity 
quantified throughout the ipsilateral striatum at 21 days (T-test: Volume, t7 = 0.6512, p = 
0.54; Optical Density, t7 = 0.7793, p = 0.46). Percentages indicate % change from 
corresponding 3 day animals (T-test: CQ ET-1, t7 = 0.8929, p = 0.4; CQ Aβ/ET-1, t8 = 
0.8825, p = 0.4). 
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Figure 19 – Effect of Chloroquine on OX-6 expression volume at 3 and 21 days. OX-6 
expression volumes at 3 (a) and 21 (b) days after surgery in untreated (white bars) and 
CQ-treated (shaded bars) ET-1 and Aβ/ET-1 animals (3d n = 6, n = 5, n = 4, n = 5; 21d n 
= 6, n = 4, n = 6, n = 5 respectively). There was no significant effect of CQ at 3 or 21 
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Figure 20 - Cellular degeneration at 3 and 21 days after surgery in Chloroquine-treated 
animals assessed by Fluoro Jade B. (a,b) Photomicrographs (16x) of degenerating cells in 
the ipsilateral striatum identified by Fluoro Jade B (FJB) at 3 and 21 (d,e) days after 
surgery in CQ ET-1 and CQ Aβ/ET-1 animals. FJB positive cells indicate cellular 
degeneration in the infarct core at 3 days after surgery, and at the border of the infarct at 
21 days after surgery. (c) Counts of FJB positive cells at 3 and (f) 21 days after surgery in 
CQ ET-1 and CQ Aβ/ET-1 animals (n = 5, n = 5, n = 4, n = 5, respectively). There were 
no significant differences between groups at 3 or 21 days in cell counts (T-test: 3d, t8 = 
1.286, p = 0.23; 21d, t7 = 0.2873, p = 0.78). Percentages are 21 day values as a percentage 
of 3 day values, which show no significant difference across time points (T-test: CQ ET-
1, t7 = 2.052, p = 0.08; CQ Aβ/ET-1, t8 = 1.268, p = 0.24). Values are the average of 3 
sections per brain. 
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Figure 21 – Effect of Chloroquine on Fluoro Jade B cell counts at 3 and 21 days. Fluoro 
Jade B (FJB) cell counts at 3 (a) and 21 (b) days after surgery in untreated (white bars) 
and CQ-treated (shaded bars) ET-1 and Aβ/ET-1 animals (3d n = 6, n = 5, n = 4, n = 5; 
21d n = 6, n = 4, n = 6, n = 5, respectively). There was no significant effect of CQ at 3 
days, however there was a significant effect of CQ at 21 days (ANOVA: 3d, F3,16 = 
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CQ ET-1 and CQ Aβ/ET-1 groups were not significantly different at 21 days in FJB-
positive cells in the striatum (Fig. 20f). CQ treatment led to a significant reduction in the 
number of FJB positive cells at 21 days in CQ Aβ/ET-1 rats (51% of Aβ/ET-1 counts, p < 
0.05) and a non-significant decrease in CQ ET-1 rats (61.5% of ET-1 rats, p > 0.05) (Fig. 
21b). 
3.2.3 NeuN Expression in Chloroquine-Treated Animals 
At 3 days after surgery there was no significant difference between CQ ET-1 and 
CQ Aβ/ET-1 animals in neuronal loss in the ipsilateral striatum (losing roughly 36% and 
19%, respectively, Fig. 22e, p > 0.05). The infarct region was poorly defined at 3 days 
(Fig 22b,d), with NeuN-positive cells present throughout the core of the infarct (Fig. 
22g,i). CQ treatment had no significant effect on neuronal loss at 3 days compared to the 
corresponding untreated groups (Fig. 24a, p > 0.05), suggesting CQ was unable to 
prevent the substantial acute neuronal loss following stroke.  
There was no significant difference in NeuN expression between 3 and 21 days 
for CQ ET-1- and CQ Aβ/ET-1 groups (p > 0.05), despite an apparent increase in NeuN 
expression in CQ ET-1 rats at 21 days after surgery. Thus while CQ was unable to 
prevent the acute neuronal loss it effectively prevented expansion of the infarct at 21 days 
after surgery, as there was some progressive neuronal loss within the infarct region which 
was well defined at 21 days with very few NeuN positive cells in the core of the infarct 
(Fig. 23g,i). At 21 days after surgery, CQ ET-1 and CQ Aβ/ET-1 groups were not 
significantly different in neuronal loss (Fig. 23e, p > 0.05). CQ treatment significantly 
improved neuronal survival at 21 days, as CQ ET-1 and CQ Aβ/ET-1 showed  
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Figure 22 – Expression of neuronal protein NeuN at 3 days after surgery in Chloroquine-
treated animals. Photomicrographs of neurons identified by NeuN in the striatum of CQ 
ET-1 and CQ Aβ/ET-1 animals at 3 days after surgery. Areas boxed in lower power 
(1.5x) photomicrographs (a-d) are shown in higher power (10x) in panels (f-i), 
demonstrating decreased NeuN expression in the infarct. (e) Counts of neurons in the 
ipsilateral striatum identified by NeuN in CQ ET-1 (n = 5) and CQ Aβ/ET-1 (n = 5) 
animals, expressed as a ratio of the contralateral striatum (T-test: t8 = 1.656, p = 0.14). 
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Figure 23 – Neuronal survival at 21 days in Chloroquine-treated animals. (a-d) 
Photomicrographs of neurons identified by NeuN in the striatum of CQ ET-1 and CQ 
Aβ/ET-1 animals at 21 days after surgery. Areas boxed in lower power (1.5x) 
photomicrographs (a-d) are shown in higher power (10x) in panels (f-i), demonstrating 
the absence of NeuN expression in the infarct. (e) Counts of neurons in the ipsilateral 
striatum identified by NeuN in CQ ET-1 (n = 4) and CQ Aβ/ET-1 (n = 5) animals, 
expressed as a ratio of NeuN expression in the contralateral striatum (T-test: t7 = 0.6088, 
p = 0.56). Percentages indicate change from corresponding 3 day animals (T-test: CQ 
ET-1, t7 = 1.907, p = 0.10; CQ Aβ/ET-1, t8 = 0.1554, p = 0.88). Values are averaged from 
3 sections per brain.  
 




Figure 24 – Effect of Chloroquine on neuronal survival at 3 and 21 days. Detection of the 
neuronal protein NeuN in the ipsilateral striatum, expressed as the ratio of contralateral 
NeuN expression, at 3 (a) and 21 days (b) after surgery in untreated (white bars) and CQ-
treated (shaded bars) ET-1 and Aβ/ET-1 animals (3d n = 6, n = 5, n = 4, n = 5; 21d n = 6, 
n = 4, n = 6, n = 5). There was no significant effect of CQ at 3 days, but there was a 
significant improvement at 21 days (ANOVA: 3d, F3,16 = 1.811, p = 0.19; 21d, F3,17 = 
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significantly greater neuronal survival (87% and 79%, respectively) compared to the 
corresponding untreated groups (p < 0.05 and < 0.01, respectively, Fig. 24b)  
3.2.4 GM3 Expression in Chloroquine-Treated Animals 
GM3 was detected at 3 days after surgery in the ipsilateral striatum of CQ-treated 
animals. CQ ET-1 and CQ Aβ/ET-1 rats were not significantly different in GM3 
expression volume (Fig. 25e, p > 0.05) or GM3 staining intensity (Fig. 25j, p > 0.05). 
GM3 positive cells were distributed throughout the infarct region (Fig. 25g,i). CQ 
treatment led to a non-significant reduction in GM3 expression volume at 3 days in CQ 
ET-1 and CQ Aβ/ET-1 rats (66.4% and 61.9% of untreated OX-6 inflammation volume, 
respectively) relative to the corresponding untreated groups (Fig. 27a, p > 0.05).  
CQ ET-1 showed a significant decrease in GM3 expression volume from 3 to 21 
days after surgery (8% of 3 day value, p < 0.05) while CQ Aβ/ET-1 showed a non-
significant decrease from 3 to 21 days (42.6% of 3 day value, p > 0.05). At 21 days, CQ 
ET-1 and CQ Aβ/ET-1 animals were not significantly different in GM3 expression 
volume (Fig. 26e, p > 0.05) or staining intensity (Fig. 26j, p > 0.05). GM3 staining 
appeared predominantly extracellular in the infarct core, with GM3 positive cells located 
mainly around the borders of the infarct (Fig. 26g,i). CQ treatment significantly reduced 
GM3 expression volume at 21 days in CQ Aβ/ET-1 animals compared to Aβ/ET-1 
animals (13.1% of Aβ/ET-1, p < 0.05) and led to a non-significant reduction in CQ ET-1 
animals compared to ET-1 animals (16.6% of ET-1, p > 0.05) (Fig. 27b).  
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Figure 25 – GM3 expression in Chloroquine-treated animals at 3 days after surgery. 
Photomicrographs of GM3 immunostaining in the ipsilateral striatum of CQ ET-1 (n = 5) 
and CQ Aβ/ET-1 (n = 5) animals at 3 days after surgery. Areas boxed in lower power 
(1.5x) photomicrographs (a-d) are shown in higher power (10x) in panels (f-i), 
demonstrating the neuronal morphology of GM3 positive cells in the infarct. (e) GM3 
expression volume and (j) GM3 staining intensity quantified throughout the ipsilateral 
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Figure 26 – GM3 expression in Chloroquine-treated animals at 21 days after surgery. (a-
d) Photomicrographs of GM3 immunostaining in the ipsilateral striatum of CQ ET-1 (n = 
4) and CQ Aβ/ET-1 (n = 5) animals at 21 days after surgery. Areas boxed in lower power 
(1.5x) photomicrographs (a-d) are shown in higher power (10x) in panels (f-i), 
demonstrating the predominantly extracellular expression of GM3. (e) GM3 expression 
volume and (j) GM3 staining intensity quantified throughout the ipsilateral striatum at 21 
days (T-test: Volume, t7 = 0.8638, p = 0.42; Optical Density, t7 = 0.465, p = 0.66). 
Percentages are 21 day values as a percentage of corresponding 3 day values, and * 
indicates significance from 3 day CQ animals (T-test: CQ ET-1, t7 = 3.259, p < 0.05; CQ 
Aβ/ET-1, t8 = 0.9986, p = 0.3472). *p < 0.05.  
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Figure 27 – Effect of Chloroquine on GM3 Expression Volume at 3 and 21 days. GM3 
expression volumes at 3 (a) and 21 (b) days after surgery in untreated (white bars) and 
CQ-treated (shaded bars) ET-1 and Aβ/ET-1 animals (3d n = 6, n = 5, n = 4, n = 5; 21d n 
= 6, n = 4, n = 6, n = 5, respectively). There was no significant effect of CQ at 3 days, 
however CQ did significantly reduce GM3 expression volume at 21 days after surgery 
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3.2.5 Linear Regression Analyses: Pleiotropic Effects of CQ 
Linear regression analysis was performed on 21 day CQ-treated animals to 
provide an estimate of the relative contribution of the pleiotropic effects of CQ on 
improving neuronal survival, as both OX-6 expression volume and GM3 expression 
volume showed negative correlations with enhanced neuronal survival in CQ-treated 
animals. Linear regression analysis between OX-6 expression volume and neuronal 
survival (%NeuN Expression) yielded an r2 of 0.89; linear regression analysis between  
GM3 expression volume and neuronal survival yielded an r2 of 0.64, suggesting the anti-
inflammatory effects of CQ had a greater impact on improving neuronal survival than its 
anti-GM3 effects. 
3.2.6 GM1 and GD1b Expression in Chloroquine-Treated Animals 
GM1 staining intensity was significantly reduced at 3 days after surgery in the 
infarct of both CQ ET-1 (p < 0.01) and CQ Aβ/ET-1 (p < 0.05) rats compared to the 
contralateral striatum (Fig. 28b,d), however they were not significantly different from one 
another (Fig. 28e, p > 0.05). GM1 expression was diffuse throughout the striatum and in 
the corpus callosum (Fig. 28a-d), with no obvious effects of CQ on GM1 expression. CQ 
treatment improved GM1 staining intensity at 3 days, as CQ ET-1 showed a significantly 
smaller deficit from the contralateral striatum than ET-1 (p < 0.05), and CQ Aβ/ET-1 
showed a non-significant improvement over Aβ/ET-1 (Fig. 29a, p > 0.05). 
At 21 days after surgery, GM1 staining intensity was significantly reduced in CQ 
Aβ/ET-1 animals compared to the contralateral striatum (p < 0.01), while CQ ET-1 rats 
showed a non-significant reduction in GM1 staining intensity in the infarct (p > 0.05).  
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Figure 28 – Effect of Chloroquine on GM1 expression at 3 and 21 days in the infarct. (a-
d) Photomicrographs (1.5x) of GM1 immunostaining in the striatum of CQ ET-1 and CQ 
Aβ/ET-1 animals at 3 and 21 (f-i) days after surgery. GM1 expression is diffuse 
throughout the striatum, yet decreased in the infarct. Quantification of reduced GM1 
expression in CQ ET-1 and CQ Aβ/ET-1 animals at 3 (e) and 21 (j) days after surgery (n 
= 5, n = 5, n = 4, n = 5, respectively) expressed as the reduction in GM1 staining intensity 
in the infarct relative to the contralateral striatum, analyzed against the expected 
difference of 0 (T-test: 3d CQ ET-1, t3 = 6.709, p < 0.01; CQ Aβ/ET-1, t2 = 6.071, p < 
0.05; 21d CQ ET-1, t1 = 1.832, p = 0.32; CQ Aβ/ET-1, t3 = 9.81, p < 0.01). There was no 
significant difference between groups at 3 or 21 days (T-test: 3d, t5 = 0.7899, p = 0.4654; 
21d, t4 = 0.8867, p = 0.43). Values are the average of 3 measurements per brain. *p < 
0.05, **p < 0.01.   
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Figure 29 – Effect of Chloroquine on GM1 expression at 3 and 21 days. Quantification of 
reduced GM1 expression expressed as the reduction in GM1 staining intensity in the 
infarct relative to the contralateral striatum at 3 (a) and 21 (b) days after surgery in 
untreated (white bars) and CQ-treated (shaded bars) ET-1 and Aβ/ET-1 animals (3d n = 
6, n = 5, n = 4, n = 5; 21d n = 6, n = 4, n = 6, n = 5, respectively). There was a significant 
effect at 3 days, as CQ partially rescued GM1 expression in CQ ET-1 animals, however 
there was no significant effect at 21 days (ANOVA: 3d, F3,11 = 6.313, p < 0.01, Tukey’s p 
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CQ ET-1 and CQ Aβ/ET-1 were not significantly different in GM1 staining intensity 
(Fig. 27j, p > 0.05) and there was no significant difference from 3 to 21 days for either 
group (p > 0.05). GM1 staining was diffuse throughout the striatum and present in the 
corpus callosum, with no obvious effect of CQ on GM1 expression (Fig. 27f-i). CQ 
treatment led to a non-significant improvement in both CQ ET-1 and CQ Aβ/ET-1 
animals over the corresponding untreated groups (p > 0.05) (Fig. 29), with a modest 
effect on reducing the deficit of GM1 staining intensity in the infarct. 
GD1b staining intensity in the infarct was significantly reduced at 3 days after 
surgery in CQ Aβ/ET-1 rats (p < 0.01), while CQ ET-1 showed a non-significant 
reduction in GD1b staining intensity in the infarct compared to the contralateral striatum. 
There was no significant difference between CQ ET-1 and CQ Aβ/ET-1 rats in GD1b 
staining intensity (Fig. 30e, p > 0.05). CQ treatment had no observable effect on GD1b 
expression at 3 days after surgery (Fig. 30a-d), and had no significant effect compared to 
untreated groups, as there were no significant differences across all groups 3 days (Fig. 
31a, p > 0.05). 
At 21 days after surgery, GD1b staining intensity in the infarct was significantly 
reduced relative to the contralateral striatum in CQ Aβ/ET-1 animals (p < 0.01), but not 
in CQ ET-1 animals (p > 0.05). CQ ET-1 and CQ Aβ/ET-1 rats were not significantly 
different from one another at 21 days in GD1b staining intensity (Fig. 30j, p > 0.05). 
There was no significant difference between 3 and 21 days in GD1b staining intensity for 
CQ ET-1 and CQ Aβ/ET-1 rats (p > 0.05). CQ treatment led to a non-significant 
improvement in CQ ET-1 over ET-1, partially reducing the deficit in GD1b staining 
intensity in the infarct (Fig. 31b, p > 0.05). 
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Figure 30 – Effect of Chloroquine on GD1b expression at 3 and 21 days in the infarct. (a-
d) Photomicrographs (1.5x) of GD1b immunostaining in the striatum of CQ ET-1 and CQ 
Aβ/ET-1 animals at 3 and 21 (f-i) days after surgery. GD1b expression is diffuse 
throughout the striatum, yet decreased in the infarct. Quantification of reduced GD1b 
expression in CQ ET-1 and CQ Aβ/ET-1 animals at 3 (e) and 21 (j) days after surgery (n 
= 5, n = 5, n = 4, n = 5, respectively) expressed as the reduction in GD1b staining 
intensity in the infarct relative to the contralateral striatum, analyzed against the expected 
difference of 0 (T-test: 3d CQ ET-1, t3 = 2.776, p = 0.7; CQ Aβ/ET-1, t2 = 15.33, p < 
0.01; 21d CQ ET-1, t3 = 5.44, p = 0.12; CQ Aβ/ET-1, t4 = 5.903, p < 0.01). There was no 
significant difference between groups at 3 or 21 days (T-test: 3d, t5 = 0.5253, p = 0.62; 
21d, t4 = 1.369, p = 0.24).  
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Figure 31 – Effect of Chloroquine on GD1b expression at 3 and 21 days. Quantification 
of reduced GD1b expression in the infarct expressed as the reduction in GD1b staining 
intensity relative to the contralateral striatum at 3 (a) and 21 (b) days after surgery in 
untreated (white bars) and CQ-treated (shaded bars) ET-1 and Aβ/ET-1 animals (3d n = 
6, n = 5, n = 4, n = 5; 21d n = 6, n = 4, n = 6, n = 5, respectively). There was no 
significant effect of CQ at 3 or 21 days (ANOVA: 3d, F3,11 = 0.38, p = 0.7664; 21d, F3,8 = 
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In line with our previous findings demonstrating synergistic pathology in a co-
morbid animal model of stroke and Aβ toxicity (Whitehead et al., 2005a, 2005b, 2007), 
this is the first study to demonstrate that Aβ toxicity can aggravate stroke-induced 
pathogenic changes in ganglioside expression. This supports our initial hypothesis and 
confirms that 1) GM3 is detectable in our unilaterial ET-1 induced striatal stroke model 
and is associated with reduced expression of complex gangliosides, neuroinflammation 
and neuronal loss; and 2) GM3 expression is synergistically enhanced in our combined 
model at 21 days after ischemia, colocalizing in neurons and degenerating cells 
suggesting that GM3 accumulation is a synergistic pathway mediating the combined 
pathological effects of stroke and Aβ toxicity. 
CQ was also tested as a proof of principle approach in preventing the pathogical 
changes in ganglioside expression, and we are the first to show that CQ can effectively 
limit GM3 expression and inflammation 21 days following stroke. This supports our 
hypothesis and confirms that 3) CQ reduced the expression of GM3 and reduced neuronal 
loss after ischemia. A proposed pathway demonstrating the interaction between stroke 
and Aβ toxicity and the pleiotropic effects of Chloroquine is shown in Fig. 32.  
4.1 Neuroinflammation 
Neuroinflammation is intimately associated with both stroke and AD 
(Ekelenboom et al., 1994; Yamashima and Oikawa, 2009), and previous efforts by our 
lab and others implicate inflammation as the primary pathway mediating the combined 
pathogenic effects when stroke and Aβ toxicity are combined (Zhang et al., 1997; 
Whitehead et al., 2005a; 2007a; Koistinaho et al., 2002) (Fig. 32). As a key component to 
the inflammatory response (Bruce-Keller, 1999; Marks et al., 2001), ramified 




Figure 32 – Proposed mechanism of Chloroquine. Chloroquine demonstrates pleiotropic 
effects in improving neuronal survival in a co-morbid model of stroke and Aβ toxicity. 
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microglia were readily detected by increased expression of OX-6 and taken as a correlate 
of neuroinflammation. Aβ had no effect on OX-6 expression in the striatum at 21 days 
after surgery, however the striatum isn’t an area that has shown to be affected by this 
model of generalized Aβ toxicity (Whitehead et al., 2005a; Cheng et al., 2006). Aβ/ET-1 
rats showed no effect of Aβ at 3 days on OX-6 expression compared to ET-1 rats, 
however Aβ-mediated effects are not expected to be acute (Jack et al, 2010). After 21 
days, both ET-1 and Aβ/ET-1 rats showed significant increases in OX-6 expression 
volume from 3 days, suggesting that the neuroinflammatory response was still active. Aβ 
toxicity had a non-additive effect on increasing OX-6 expression volume at 21 days, 
suggesting potentiation of the inflammatory response as reported in other co-morbid 
models of stroke and AD (Zhang et al., 1997; Sheng et al., 2003; Koistinaho et al., 2002).  
In the presence of Aβ toxicity there was significant progressive growth of the 
infarct, as also reported by Whitehead et al. (2007a). Unlike Whitehead et al. (2007a) 
however, ET-1 also showed a progressive increase (though not as large as Aβ/ET-1) and 
we did not see a significant difference in OX-6 expression volume between ET-1 and 
Aβ/ET-1 over time. This discrepancy is likely a result of using a greater concentration of 
ET-1 (60 pmol vs 6 pmol) and thus a larger initial injury, revealing a potential ceiling 
effect of Aβ toxicity in enhancing the inflammatory response. Physical barriers - such as 
the corpus callosum and lateral ventricle – likely restrict the spread of the uninhibited 
growth of the infarct in the striatum, which may also limit the observable effects of the 
combination of Aβ toxicity and stroke. 
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CQ treatment had no effect on reducing OX-6 expression at 3 days, however it 
reduced OX-6 expression volume in both CQ ET-1 (29.9% of ET-1) and CQ Aβ/ET-1 
(22.1% of Aβ/ET-1) rats after 21 days by reducing the progressive increase in OX-6 
expression volume. The primary injury is largely irreversible following ischemia 
(Obrenovitch, 1995) however limiting the secondary neuronal loss may be an effective 
strategy for therapeutic intervention.  
4.2 GM3 Expression 
GM3 was not detected in Aβ or Reverse rats at 21 days after surgery. Kruetz et al. 
(2011) showed that hippocampal slices incubated with pre-aggregated Aβ25-35 increased 
GM3 expression concomitantly with cell death, while soluble Aβ25-35 had no effect on 
GM3 expression. However others have reported that soluble Aβ is more neurotoxic than 
the insoluble Aβ fibrils found in amyloid plaques (Benilova et al., 2012), highlighting the 
need for consensus on the most accurate way to model Aβ toxicity. Kracun et al. (1991) 
demonstrated that GM3 accumulated in regions of neurodegeneration in AD brains, and 
hypothesized that it was due to the accelerated lysosomal breakdown of complex 
gangliosides. It was later shown in an ex vivo model of AD that AD patients show 
enhanced β-galactosidase activity (Emiliani et al., 2003) – which is responsible for 
degradation of complex gangliosides into GM3 – and that β-galactosidase activity 
correlated with the severity of dementia (Pitto et al., 2004). The accumulation of GM3 
was also found to correlate with CAA (Oikawa et al., 2009; Yu et al., 2012), however it is 
not clear whether GM3 accumulation occurs early or after the onset of AD pathogenesis.  
Glutamate toxicity is the primary mechanism responsible for the propagation of 
stroke damage (Simon et al., 1984), leading to generation of ROS which cause oxidative 
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stress and massive cell death (Yamashima and Oikawa, 2009). In the present experiment, 
the confirmation of GM3 expression in our model of striatal infarct lends further support 
that GM3 is a viable therapeutic target for ischemic stroke, as increased GM3 levels have 
been shown to mediate the generation of ROS following glutamate toxicity (Sohn et al., 
2006) and GM3 expression had previously only been demonstrated in MCAO models of 
stroke (Kwak et al., 2005; Whitehead et al., 2011). Aβ toxicity had no effect on ET-1 
induced expression of GM3 at 3 days, however the combination of stroke and Aβ toxicity 
resulted in a synergistic increase in GM3 expression at 21 days in Aβ/ET-1 rats. To our 
knowledge this is the first study to demonstrate that the stroke-induced accumulation of 
GM3 can be potentiated by Aβ toxicity. 
In agreement with Marconi et al. (2005), GFAP-positive astrocytes did not co-
localize with GM3, however GM3 did co-localize with IbA-1 positive macrophages: 
Marconi et al. (2005) found microglia were not positive for GM3 in the human CNS, yet 
also stated that ganglioside expression studies often show conflicting results between 
models. GM3 is expressed by peripheral monocytes (Kiguchi et al., 1990) and is believed 
to control their differentiation into resident macrophages, as observed in atherosclerotic 
lesions (Gracheva et al., 2009) where there is high inflammatory involvement. The 
relationship between GM3 expression and TNFα – an inflammatory cytokine - is far from 
clear (Prokazova et al., 2009; Inokuchi, 2011) but GM3 may itself by an inflammatory 
signal by controlling macrophage differentiation, or indirectly by regulating TNFα 
expression. 
The two previous studies to detect GM3 following stroke proposed very different 
explanations on the role of GM3 in the infarct: Kwak et al. (2005) suggested that GM3 
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accumulation is a neuroprotective response indicating increased ganglioside biosynthesis, 
while Whitehead et al. (2011) proposed that GM3 plays a role in the expansion of the 
infarct over time. The majority of GM3 positive cells exhibited a neuronal morphology, 
which was confirmed by immunofluorescence and co-localization of GM3 with NeuN. 
The cellular expression pattern of GM3 appeared to propagate from the core of the infarct 
into the periphery from 3 to 21 days, suggesting expansion of the infarct into the 
surrounding penumbra in support of Whitehead et al. (2011). At 21 days after surgery 
GM3 positive cells were largely absent within the necrotic core, where the expression 
pattern of GM3 was largely extracellular. Gangliosides can be shed from neuronal 
membranes as the result of normal membrane turnover (Malisan and Testi, 2002), and 
during degenerative processes there is increased membrane turnover (Miyatani et al., 
1990; Trbojevic-Cepe et al., 1991; Tarvonen-Schroder et al., 1997; Andersson et al., 
1998). The role of non-cell associated gangliosides is not yet clear (Malisan and Testi, 
2002), however increased GM3 levels in the CSF are indicative of BBB dysfunction or 
cerebral hemorrhage (Trbojevic-Cepe et al., 1991), as GM3 is the major serum 
ganglioside (Lopez and Schnaar, 2009).  
Having shown a drastic increase in GM3 expression levels, we investigated the 
expression of complex gangliosides in order to characterize their expression in the infarct 
in relation to the accumulation of GM3. Our results suggest that expression of complex 
gangliosides is reduced in the infarct at 3 and 21 days. Despite a drastic increase in GM3 
that was potentiated by Aβ, our results only showed a modest reduction in GM1 and 
GD1b expression that was not significantly enhanced in the presence of Aβ toxicity. It is 
well-established that ganglioside levels are reduced following stroke (Rastogi et al., 1968; 
	   	   	   	   	  
	  103	  
Domanska-Janik et al., 1982; Qi and Xue, 1991; Ramirez et al., 2003), however we were 
limited by our experimental design and could not quantify total ganglioside content nor 
compare between ganglioside species by immunohistochemistry. These results do still 
provide support to the hypothesis that GM3 accumulation in the infarct is the result of the 
degradation of complex gangliosides and not increased ganglioside biosynthesis. 
Interestingly, at 21 days both GM1 and GD1b appeared concentrated around the border 
of the infarcted tissue similar to the results of Whitehead et al. (2011), who theorized that 
this up-regulation may be an effort to potentiate neurotrophic effects in neighbouring 
tissue. In support of this idea, Marconi et al. (2005) showed that astrocytes – which 
function to support neuronal survival (Akasako et al., 2011) – co-express GM1 and 
GD1b. We did not however determine the cellular expression patterns of GM1 and GD1b 
via immunofluorescence to further support this hypothesis.  
 Due to its lysomotropic properties, CQ has been used in vitro to inhibit the 
degradation of complex gangliosides to GM3 (Riboni et al., 1991,1995), however this is 
the first study to demonstrate that CQ is effective in vivo as a novel therapeutic in 
preventing the accumulation of GM3 following stroke. At 3 days, CQ reduced GM3 
expression volume by 34% and 38% in CQ ET-1 and CQ Aβ/ET-1 animals, respectively, 
compared to the corresponding untreated animals. By 21 days, CQ treatment reduced 
GM3 expression volume to 13% and 16%, respectively, of the corresponding untreated 
animals. However, CQ had less of an effect on preserving the expression of complex 
gangliosides, as CQ only showed a slight improvement that reduced the deficit in staining 
intensity between the infarct and the contralateral striatum. This is likely due to the 
limitations inherent in the analysis of the immunostaining, which was measured as a ratio 
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of staining intensity in the infarct compared to the contralateral striatum: CQ can’t 
increase expression above 100% of the contralateral striatum by preventing degradation, 
as it is also acting upon the contralateral striatum. Future studies with CQ that test the 
total ganglioside content could provide important evidence supporting further testing with 
CQ as a therapeutic for stroke.  
4.3 Neurodegeneration 
Ischemia triggers both apoptotic and necrotic cell death and results in massive 
cellular loss (Gabryel et al., 2012), which is enhanced in the presence of Aβ-toxicity 
(Whitehead et al., 2005a; 2007a; Zhang et al., 1997; Koistinaho et al., 2002). 
Neurodegeneration was assessed with FJB, a marker of cellular degeneration nonspecific 
for cell type or type of cell death (Schmued and Hopkins, 2000; Damjanac et al., 2006) 
and NeuN, a neuronal protein marker, as complementary approaches: FJB positive cells 
were counted in the ipsilateral striatum, while NeuN expressing cells in the ipsilateral 
striatum were counted and expressed as a ratio of NeuN expressing cells in the 
contralateral striatum.  
At 3 days there was extensive neurodegeneration in the ipsilateral striatum, with 
ET-1 and Aβ/ET-1 losing 35% and 40% of NeuN-expressing cells, and FJB positive cells 
distributed extensively throughout the infarct. Aβ toxicity had no effect on 
neurodegeneration at 3 days, though it has been reported to increase neuronal 
susceptibility to excitotoxic damage (Koh, Yang and Cotman, 1990). It is worthwhile to 
note that during surgery, Aβ toxicity was induced immediately prior to the ischemic 
striatal infarct, and Aβ effects are not expected to be acute (Jack et al., 2010), while other 
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reports were performed in transgenic AD mice, which are exposed to elevated 
concentrations of Aβ from birth (Zhang et al., 1997; Koistinaho et al., 2002). Regardless, 
the progressive neuronal loss following stroke from 3 to 21 days was greater in the 
presence of Aβ toxicity, as Aβ/ET-1 rats demonstrated ongoing cellular degeneration at 
21 days, as well as significantly greater neuronal loss by 21 days compared to ET-1 rats 
(42% in ET-1 rats and 58% in Aβ/ET-1 rats). At 21 days, the necrotic core of the infarct 
was void of FJB-positive and NeuN-expressing cells, with FJB positive cells located 
around the periphery of the infarct showing a similar pattern of propagation as GM3-
positive cells. FJB co-localized with GM3 cells by immunofluorescence, suggesting that 
GM3 accumulation is involved in the expansion of the infarct into the penumbra 
(Whitehead et al., 2011).  
The results of the FJB and NeuN quantification were complementary, though not 
identical, and there are several explanations for this discrepancy. First, the two markers 
were quantified differently in order to allow for appropriate analyses. Second, there is the 
possibility that neurons may reduce NeuN expression without subsequently dying; and 
third, that unlike NeuN, FJB is not a cell-specific marker and has shown to pick up 
degenerating microglia and astrocytes as well as neurons (Damjanac, 2006).  
CQ treatment was unable to prevent the acute neurodegeneration at 3 days even 
with 3 days of pretreatment, however it attenuated the progressive neurodegeneration 
from 3 to 21 days, effectively inhibiting growth of the infarct resulting in significantly 
improved neuronal survival at 21 days in both CQ ET-1 and CQ Aβ/ET-1 rats compared 
to the corresponding untreated groups (28% and 34% improvement, respectively). CQ 
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Aβ/ET-1 rats showed no effect of Aβ toxicity at 3 days, however in the presence of Aβ 
stroke resulted in greater ongoing cellular degeneration from 3 to 21 days.  
Linear regression analyses suggests that CQ had its greatest effect on improving 
neuronal survival at 21 days with its anti-inflammatory effect, specifically in reducing 
OX-6 expression volume. However, the correlation between reduced GM3 expression 
volume and improved neuronal survival suggests that the reduction in GM3 also had an 
effect on improving neuronal survival. Together, these results suggest that inflammation 
is the primary mechanism underlying the interaction between stroke and Aβ toxicity, and 
that along with GM3 accumulation both contribute to neurodegeneration.  
4.4 Limitations 
There are some limitations to this study, however they are likely to be resolved by 
future experiments. The major limitation to this study is that CQ-treated animals were not 
generated simultaneously with untreated animals in an effort to reduce the number of 
animals used. However, all animals were randomly assigned to their experimental groups 
and the same individual performed all CQ injections and surgeries to ensure consistency. 
This experiment was a proof-of-principle study to determine if CQ was able to augment 
GM3 expression, and CQ was administered in a pre-treatment paradigm. As this is the 
first study to use CQ as a therapeutic for stroke, the treatment regimen may not have been 
optimal and therefore generated a less robust outcome. CQ warrants future investigations, 
however they must be carried out at various dosages as randomized control studies in 
order to determine the clinical viability of CQ.  
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Another limitation of the present study is that histological benefit can occur in the 
absence of a functional benefit following stroke (Hiltunen et al., 2009). It is important to 
demonstrate a functional impairment in our stroke model (i.e. adhesive removal test, grip 
strength) and test if CQ treatment provides a functional improvement as well as a 
histological improvement in future studies.  
4.5 Future studies 
The identification of GM3 accumulation as a point of synergism between stroke 
and Aβ toxicity (Fig. 32) and its potential role in expansion of the infarct (Whitehead et 
al., 2011) may provide mechanistic insight into the bidirectional relationship between 
stroke and Aβ toxicity. In line with the ex vivo work of Pitto et al. (2004) in which GM3 
levels were correlated with the degree of cognitive impairment in AD patients, our work 
correlated GM3 expression with neuronal loss following stroke. Sohn et al. (2006) 
concluded that therapeutic strategies for neurodegenerative disorders should be focused 
on controlling GM3 levels, however few viable or effective strategies have been tested. 
The present study supports the theory that GM3 accumulation is the result of the 
degradation of complex gangliosides (Kracun et al., 1991). This is the first study to 
selectively prevent the accumulation of GM3 without depleting all other ganglioside 
species (Sohn et al., 2006; Akasako et al., 2011). CQ provides a novel therapeutic 
approach in managing GM3, while also displaying anti-inflammatory properties, and 
warrants future investigation to delineate these effects. Future studies with CQ can be 
carried out to determine if CQ also improves neuronal survival by acting via sigma-1 
receptors (Hirata et al., 2011) or via inhibition of autophagy, which have both proven 
beneficial following stroke (Zhang et al., 2010, 2011).  
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To improve our understanding of the regulation of ganglioside expression 
following stroke and the effects of CQ on complex ganglioside expression, future studies 
by our lab will employ MALDI mass spectrometry imaging. MALDI imaging allows for 
the simultaneous imaging of all major ganglioside species in situ and the semi-
quantitative analysis of ganglioside levels (Chan et al., 2009; Sugiura et al., 2008; 
Whitehead et al., 2011), circumventing any issues with immunohistochemistry targeted 
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Summary of Key Findings 
1. Aβ and Reverse animals showed no inflammation, neurodegeneration or GM3 
expression in the striatum at 21 days.  
2. ET-1 and Aβ/ET-1 groups showed no significant differences at 3 days.  
3. Aβ/ET-1 showed significantly greater neuronal loss and GM3 expression volume 
than ET-1 at 21 days. 
4. GM1 and GD1b expression was significantly reduced in the infarct at 3 and 21 
days. 
5. Immunofluorescence indicated co-localization of GM3 with NeuN, FJB and IbA-
1. 
6. CQ treatment had no significant effect at 3 days. 
7. CQ treatment significantly improved neuronal survival, reduced OX-6 expression 
volume and GM3 expression volume at 21 days, and partially reduced the deficit 
of complex ganglioside expression in the infarct. 
8. Simple linear regression with neuronal survival at 21 days indicated an r2 of 0.89 
for OX-6 expression volume, and 0.64 for GM3 expression volume.   
Conclusions 
The combination of stroke and Aβ toxicity led to synergistic inflammation and 
pathological ganglioside expression, resulting in significant neuronal loss in the Wistar 
rat. Chloroquine treatment for 7 days, beginning 3 days prior to ischemia, improved 
neuronal survival and reduced inflammation and accumulation of GM3, suggesting it 
may have improved outcomes by limiting the neurotoxic effects of inflammation and by 
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preventing the degradation of complex gangliosides. Together, these findings suggest that 
stroke and Aβ toxicity pathways converge upon the neuroinflammatory cascade as well 
as the pathological accumulation of GM3, and that Chloroquine holds promise as a novel 
treatment to improve neuronal survival following stroke.  
This study provides critical support for the identification of GM3 as a point of 
synergism between stroke and Aβ toxicity, as well as a potential mechanism for 
preventing the accumulation of GM3 while maintaining expression of complex 
gangliosides which are critical for neuronal functioning and repair. Aberrant GM3 
expression has been implicated in stroke (Kwak et al., 2005; Sohn et al., 2006; Whitehead 
et al., 2011), diabetes mellitus (Inokuchi, 2011), atherosclerosis (Gracheva et al., 2009), 
LDL cholesterol levels (Inokuchi, 2011) and AD (Kracun et al., 1991; Pitto et al., 2004; 
Yanagisawa et al., 1995) and thus may represent a point of overlap between multiple risk 
factors for AD and AD itself, making it a potentially ideal biomarker as well as an 
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